

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 06:54:38 ; Search time 1052 Seconds
(without alignments)
9902.920 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215
Sequence: 1 ataacgctagcctgagggag.....gacagagagcaggagaccgc 215

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues

Total number of hits satisfying chosen parameters: 9416466

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenBank:*
1: gb_ba:*
2: gb_hcg:*
3: gb_in:*
4: gb_cm:*
5: gb_ov:*
6: gb_pac:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_scs:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	215	100.0	215	6	BD273753
2	215	100.0	215	6	BD273754
3	215	100.0	215	6	AX036038
4	215	100.0	215	6	AX036039
5	215	100.0	533	6	AR084816
6	215	100.0	533	6	I21401
7	215	100.0	533	6	I21401
8	215	100.0	2465	6	E12384
9	215	100.0	2691	6	CO812310
10	215	100.0	2691	6	CO818823
11	215	100.0	2691	6	AR262810
12	215	100.0	2691	6	HUMHSP7D
13	215	100.0	4360	9	AB018045
14	214.6	99.8	488	9	S52686
15	214	99.5	5387	6	CO806661
16	214	99.5	59836	9	AL929592
17	214	99.5	125350	2	AC020768
18	214	99.5	178460	2	AL139040
19	214	99.5	179894	9	AL662834

C	20	214	99.5	180283	9	AF134726	AF134726	Homo sapi
	21	214	99.5	234314	2	BX005460	BX005460	Homo sapi
	22	213.4	99.3	549	9	HSHP70A	HSHP70A	Human hsp 7
	23	212.4	98.8	2700	9	HUMHSP	HUMHSP	Human MHC c
	24	212.4	98.8	97255	2	CR759915	CR759915	Homo sapi
	25	212.4	98.8	100000	9	AP00050351	AP00050351	Homo sapi
	26	212.4	98.8	113582	9	AL671762	AL671762	Human DNA
	27	212.4	98.8	122792	2	CR388202	CR388202	Homo sapi
	28	210.4	97.9	1903	6	AX833899	AX833899	Sequence
	29	210.4	97.9	1903	6	AK096017	AK096017	Homo sapi
	30	203	94.4	214	6	BD273761	BD273761	Expressio
	31	203	94.4	214	6	AX036046	AX036046	Sequence
	32	191.4	89.0	2412	6	AR531603	AR531603	Sequence
	33	187.4	87.2	420	6	AR413190	AR413190	Sequence
	34	187.4	87.2	420	6	AX970024	AX970024	Sequence
	35	187.4	87.2	420	6	BD108743	BD108743	EST and e
	36	186.2	86.6	511	6	AX194930	AX194930	Sequence
	37	173.4	80.7	2379	9	BC002453	BC002453	Homo sapi
	38	163.6	76.1	2876	6	AX770499	AX770499	Sequence
	39	163.6	76.1	2876	9	HUMHSP2	M59630	Human MHC c
	40	163.6	76.1	3533	9	AY559742	AY559742	Homo sapi
	41	163.6	76.1	97255	2	CR759915	CR759915	Homo sapi
	42	162	75.3	125350	2	AC020768	AC020768	Homo sapi
	43	156.8	72.9	957	9	BC001876	BC001876	Homo sapi
	44	156.8	72.9	957	6	AR531604	AR531604	Sequence
	45	150.8	70.1	2537	9	BC063507	BC063507	Homo sapi

ALIGNMENTS

RESULT 1	BD273753	215 bp	DNA	linear	PAT 17-JUL-2003
LOCUS	BD273753				
DEFINITION	Expressio				
ACCESSION	BD273753				
VERSION	BD273753.1				GI:33083521
KEYWORDS	JP 2002537843-A/1.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.				
TITLE	Coste,H.J. and Ellis,J.H.				
JOURNAL	Patent: JP 2002537843-A 1 12-NOV-2002;				
COMMENT	GLAXO GROUP LTD				
OS	Homo sapiens (human)				
PN	JP 2002537843-A/1				
PF	12-NOV-2002				
PR	09-MAR-2000 JP 2000603406				
PI	11-MAR-1999 GB 9905498.3				
C12N15/02	HERVE JEAN-CLEMENT COSTE, JONATHAN HENRY ELLIS PC				
C12N15/09	A61K38/44, A61K39/00, A61K48/00, C07K14/46, C12N5/10, PC				
PC	C12P21/02,				
CC	C12N15/00, C12N5/00, A61K37/50				
CC	Expression				
EH	Key				
FT	source				
FT	1. .215				
FEATURES	Location/Qualifiers				
source	1. .215				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				

ORIGIN

Query Match 100.0%; Score 215; DB 6; Length 215;
Best local Similarity 100.0%; Pred. No. 1.3e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATTAACGCTAGCCTAGAGAGCTGCTGCGACAGCTCCACTACCTTTTTCGAGAGTACTCCC 60

Db 1 ATACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCC 60
Qy 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGGTGAGTTT 120
Db 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGGTGAGTTT 120
Qy 121 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCAGACCCCAA 180
Db 121 CCGGGGTCCGGAAGAACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCAGACCCCAA 180
Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCGC 215
Db 181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCGC 215

RESULT 2
BD273754 215 bp RNA linear PAT 17-JUL-2003
LOCUS BD273754
DEFINITION Expression.
ACCESSION BD273754 GI:33083522
VERSION JP 2002537843-A/2.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE Coote,H.J. and Ellis,J.H.
AUTHORS Coote,H.J. and Ellis,J.H.
TITLE Expression
JOURNAL Patent: JP 2002537843-A 2 12-NOV-2002;
GLAXO GROUP LTD
COMMENT OS Homo sapiens (human)
PN JP 2002537843-A/2
PD 12-NOV-2002
PE 09-MAR-2000 JP 200603406
PF 11-MAR-1999 GB 9905498.3
PI HERVE JEAN-CLEMENT COSTE,JONATHAN HENRY ELLIS PC
C12N15/09,A61K38/44,A61K39/00,A61K48/00,C07K14/46,C12N5/10, PC
C12P21/02,
PC C12N15/00,C12N5/00,A61K37/50
CC Expression
FH Key Location/Qualifiers
FT source 1..215
FT Location/Qualifiers
FT 1..215 /organism='Homo sapiens (human)'.
FT 1..215 /organism='Homo sapiens'
FT /mol_type='genomic RNA'
FT /db_xref='taxon:9606'

ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 215;
Best Local Similarity 100.0%; Pred. No. 1,3e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

AX036038 215 bp DNA linear PAT 15-NOV-2000
LOCUS AX036038
DEFINITION Sequence 1 from Patent WO0053785.
ACCESSION AX036038
VERSION AX036038.1 GI:11191577
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE Coote,H.J. and Ellis,J.H.
AUTHORS Coote,H.J. and Ellis,J.H.
TITLE Expression
JOURNAL Patent: WO 0053785-A 1 14-SEP-2000;
COSTE HERVE JEAN CLEMENT (FR) ; GLAXO GROUP LTD (GB) ; ELLIS
JONATHAN HENRY (GB)
FEATURES
source 1..215
Location/Qualifiers
1..215 /organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 215;
Best Local Similarity 100.0%; Pred. No. 1,3e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

AX036039 215 bp RNA linear PAT 15-NOV-2000
LOCUS AX036039
DEFINITION Sequence 2 from Patent WO0053785.
ACCESSION AX036039
VERSION AX036039.1 GI:11191578
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE Coote,H.J. and Ellis,J.H.
AUTHORS Coote,H.J. and Ellis,J.H.
TITLE Expression
JOURNAL Patent: WO 0053785-A 2 14-SEP-2000;
COSTE HERVE JEAN CLEMENT (FR) ; GLAXO GROUP LTD (GB) ; ELLIS
JONATHAN HENRY (GB)
FEATURES
source 1..215
Location/Qualifiers
1..215 /organism='Homo sapiens'
/mol_type='unassigned RNA'
/db_xref='taxon:9606'

ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 215;
Best Local Similarity 100.0%; Pred. No. 1,3e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCC 60

Db	1	ATTAACGGGTACCTGAGAGAGCTGCTGCGACAGTCCACTACTCTTTTTCGAGAGTGACTCCC	60		
Qy	61	GTGTGCCAAGGCTTCCGAGCCGAACCTGTGCGGCTGCGACGACCCGGCGGCTGGAATT	120		
Db	61	GTGTGCCAAGGCTTCCGAGCCGAACCTGTGCGGCTGCGACGACCCGGCGGCTGGAATT	120		
Qy	121	CCGGCGTCCGGAAGGACCGGACTCTTCTTCGCGGATTCGAGTGTCCGTTTCCAGCCCCCA	180		
Db	121	CCGGCGTCCGGAAGGACCGGACTCTTCTTCGCGGATTCGAGTGTCCGTTTCCAGCCCCCA	180		
Qy	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC	215		
Db	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC	215		
RESULT 5	AR084816	533 bp	DNA	linear	PAT 01-SEP-2000
LOCUS	AR084816				
DEFINITION	Sequence 2 from patent US 5981224.				
ACCESSION	AR084816				
VERSION	AR084816.1	GI:10011587			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 533)				
AUTHORS	Kowalski,J., Gilbert,S. and Zamb,T.J.				
TITLE	Bovine heat shock promoter and uses thereof				
JOURNAL	Patent: US 5981224-A 2 09-NOV-1999;				
FEATURES	location/Qualifiers				
source	1..533				
ORIGIN	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	100.0%;	Score 215;	DB 6;	Length 533;	
Best Local Similarity	100.0%;	Pred. No. 1.2e-46;			
Matches 215; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;	
Qy	1	ATTAACGGGTACCTGAGAGAGCTGTGCGACAGTCCACTACTCTTTTTCGAGAGTGACTCCC	60		
Db	235	ATTAACGGGTACCTGAGAGAGCTGTGCGACAGTCCACTACTCTTTTTCGAGAGTGACTCCC	294		
Qy	61	GTGTGCCAAGGCTTCCGAGCCGAACCTGTGCGGCTGCGACGACCCGGCGGCTGGAATT	120		
Db	295	GTGTGCCAAGGCTTCCGAGCCGAACCTGTGCGGCTGCGACGACCCGGCGGCTGGAATT	354		
Qy	121	CCGGCGTCCGGAAGGACCGGACTCTTCTTCGCGGATTCGAGTGTCCGTTTCCAGCCCCCA	180		
Db	355	CCGGCGTCCGGAAGGACCGGACTCTTCTTCGCGGATTCGAGTGTCCGTTTCCAGCCCCCA	414		
Qy	181	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC	215		
Db	415	TCTCAGAGCCGAGCCGACAGAGACGAGGAAACCGC	449		
RESULT 6	121401	533 bp	DNA	linear	PAT 07-OCT-1996
LOCUS	121401				
DEFINITION	Sequence 2 from patent US 5521084.				
ACCESSION	121401				
VERSION	121401.1	GI:1601755			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 533)				
AUTHORS	Kowalski,J., Gilbert,S. and Zamb,T.J.				
TITLE	Bovine heat shock promoter and uses thereof				
JOURNAL	Patent: US 5521084-A 2 28-MAY-1996;				
FEATURES	location/Qualifiers				
source	1..533				

ORIGIN	/organism="unknown" /mol_type="unassigned DNA"			
Query Match	100.0%;	Score 215;	DB 6;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 1.2e-46;		
Matches	215;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1	ATAACGGCTAGCTCGAGAGGTGCTGGACAGTCCACTTACTCTTTTTCGAGAGTGAATCCC	60	
Db	235	ATAACGGCTAGCTCGAGAGAGCTGCTGGACAGTCCACTTACTCTTTTTCGAGAGTGAATCCC	294	
QY	61	GTTGTCCTCAAGAGCTTCCACAGAGCCGACCTGTGCGAGTGCAGAGCACCAGCGCGTGAAGTTT	120	
Db	295	GTTGTCCTCAAGAGCTTCCACAGAGCCGACCTGTGCGAGTGCAGAGCACCAGCGCGTGAAGTTT	354	
QY	121	CCGGCGTCCTCGAAGAGACCGAGCTCTTCTCGCGATTCAGATGTCGTTTCCAGCCCCCA	180	
Db	355	CCGGCGTCCTCGAAGAGACCGAGCTCTTCTCGCGATTCAGATGTCGTTTCCAGCCCCCA	414	
QY	181	TCTCAGAGCCGAGCCGACAGAGAGCAGAGCAGGAAACCGC	215	
Db	415	TCTCAGAGCCGAGCCGACAGAGAGCAGAGCAGGAAACCGC	449	
RESULT 7				
195741	Sequence 1	533 bp	DNA	linear
LOCUS	195741	195741	195741	PAT 01-DEC-1998B
DEFINITION	Sequence 2 from patent US 5733745.			
ACCESSION	195741			
VERSION	195741.1	GI:3940211		
KEYWORDS				
ORGANISM	Unknown.			
SOURCE	Unknown.			
REFERENCE	1 (bases 1 to 533)			
AUTHORS	Kowalewski, J., Gilbert, S. and Zamb, T. J.			
TITLE	Bovine heat shock promoter and uses thereof			
JOURNAL	Patent: US 5733745-A 2 31-MAR-1998;			
FEATURES	Location/Qualifiers			
source	1..533			
	/organism="unknown"			
	/mol_type="unassigned DNA"			
ORIGIN				
Query Match	100.0%;	Score 215;	DB 6;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 1.2e-46;		
Matches	215;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1	ATAACGGCTAGCTCGAGAGGTGCTGGACAGTCCACTTACTCTTTTTCGAGAGTGAATCCC	60	
Db	235	ATAACGGCTAGCTCGAGAGAGCTGCTGGACAGTCCACTTACTCTTTTTCGAGAGTGAATCCC	294	
QY	61	GTTGTCCTCAAGAGCTTCCACAGAGCCGACCTGTGCGAGTGCAGAGCACCAGCGCGTGAAGTTT	120	
Db	295	GTTGTCCTCAAGAGCTTCCACAGAGCCGACCTGTGCGAGTGCAGAGCACCAGCGCGTGAAGTTT	354	
QY	121	CCGGCGTCCTCGAAGAGACCGAGCTCTTCTCGCGATTCAGATGTCGTTTCCAGCCCCCA	180	
Db	355	CCGGCGTCCTCGAAGAGACCGAGCTCTTCTCGCGATTCAGATGTCGTTTCCAGCCCCCA	414	
QY	181	TCTCAGAGCCGAGCCGACAGAGAGCAGAGCAGGAAACCGC	215	
Db	415	TCTCAGAGCCGAGCCGACAGAGAGCAGAGCAGGAAACCGC	449	
RESULT 8				
E12384	Human cDNA encoding HSP70.	2465 bp	DNA	linear
LOCUS	E12384	E12384	E12384	PAT 27-APR-1998B
ACCESSION	E12384.1	GI:3251217		
VERSION	E12384.1	GI:3251217		
KEYWORDS	UP 1996322577-A/1.			

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS 1 (bases 1 to 2465)
TITLE Demura,H., Nomura,K., Shimizu,S., Raaij,T.H. and Hisekawa,Y.
TRANSCRIPTIONAL ABNORMALITY OF INTRACELLULAR HSP70MRNA UNDER
SUSTAINED STRESS LOAD CONTAINING HUMAN ACUTENESS AND CHRONICITY AND
ITS APPLICATION (APPLICATION OF BOTH TRANSCRIPTIONAL EXPRESSION OF
NEW HUMAN INTRACELLULAR HSP70MRNA AND TRANSCRIPTIONAL ABNORMALITY
OF HSP70 MRNA)
JOURNAL Patent: JP 1996322577-A 1 10-DEC-1996;
HOKEN KAGAKU KENKYUSHO:KK
COMMENT OS Homo sapiens (human)
PN JP 1996322577-A/1
PD 10-DEC-1996
PF 01-JUN-1995 JP 199518581
PI DEMURA HIROSHI, NOMURA KAORU, SHIMIZU SHOICHI, PI RAARI
TABURAYI HANKINZU
PI HISAKAWA YOSHIZO
PC C12N15/09,C12P21/02,C12Q1/68;
CC strandedness: Double;
CC topology: Linear;
FH Key location/Qualifiers
FT source 1..2465
FT /organism='Homo sapiens'
FT /tissue type='lymphocyte'
FT CDS 263..2185
FT /product='HSP70'
FT mutation join(1..143,306,,2465)
FT /note= alternative splicing caused by stress'.
FEATURES
source location/Qualifiers
1..2465
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 2465;
Best Local Similarity 100.0%; Pred. No. 1.1e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATAAAGCGCTAGAGCTGAGAGCTGCTCCGACAGCTCACTACCTTTTCGAGAGTACTCCC 60
DB 48 ATAAAGCGCTAGAGCTGAGAGCTGCTCCGACAGCTCACTACCTTTTCGAGAGTACTCCC 107
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGCGGTGAGAGCGAGCGGCGTCCAGATT 120
DB 108 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGCGGTGAGAGCGAGCGGCGTCCAGATT 167
QY 121 CCGGCGTCCGGAAGAGCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 180
DB 168 CCGGCGTCCGGAAGAGCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 227
QY 181 TCTCAGAGCGGAGCGAGCGAGAGCGAGGAAACCCG 215
DB 228 TCTCAGAGCGGAGCGAGCGAGAGCGAGGAAACCCG 262
RESULT 9
LOCUS CQ812310 2691 bp DNA linear PAT 24-MAY-2004
DEFINITION Sequence 62 from Patent WO2004038020.
ACCESSION CQ812310
VERSION CQ812310.1 GI:47601930
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
Witlig,R., Poustka,A., Mollenhauer,J. and Schadenorrf,D.

TITLE Target genes for the diagnosis and treatment of cancer
JOURNAL Patent: WO 2004038020-A 62 06-MAY-2004;
AUTHORS Deutsches Krebsforschungszentrum Stiftung des oeffentlichen n Rechts
REFERENCE (DE)
FEATURES
source location/Qualifiers
1..2691
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
misc_feature 1..2691
/note="M11717"
ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 2691;
Best Local Similarity 100.0%; Pred. No. 1.1e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATAAAGCGCTAGAGCTGAGAGCTGCTCCGACAGCTCACTACCTTTTCGAGAGTACTCCC 60
DB 274 ATAAAGCGCTAGAGCTGAGAGCTGCTCCGACAGCTCACTACCTTTTCGAGAGTACTCCC 333
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGCGGTGAGAGCGAGCGGCGTCCAGATT 120
DB 334 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGCGGTGAGAGCGAGCGGCGTCCAGATT 393
QY 121 CCGGCGTCCGGAAGAGCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 180
DB 394 CCGGCGTCCGGAAGAGCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 453
RESULT 10
LOCUS CQ818823 2691 bp DNA linear PAT 07-JUN-2004
DEFINITION Sequence 6 from Patent WO2004039412.
ACCESSION CQ818823
VERSION CQ818823.1 GI:48427426
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
JOURNAL 1
Doiron,B., Pownall,S., Cheung,A. and Hsu,E.
Compositions for cancer treatment
Patent: WO 2004039412-A 6 13-MAY-2004;
Engine, Inc. (CA)
FEATURES
source location/Qualifiers
1..2691
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 2691;
Best Local Similarity 100.0%; Pred. No. 1.1e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATAAAGCGCTAGAGCTGAGAGCTGCTCCGACAGCTCACTACCTTTTCGAGAGTACTCCC 60
DB 274 ATAAAGCGCTAGAGCTGAGAGCTGCTCCGACAGCTCACTACCTTTTCGAGAGTACTCCC 333
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGCGGTGAGAGCGAGCGGCGTCCAGATT 120
DB 334 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGGCGGTGAGAGCGAGCGGCGTCCAGATT 393
QY 121 CCGGCGTCCGGAAGAGCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 180
DB 394 CCGGCGTCCGGAAGAGCGAGCTTTCTCGCGGATCCAGTGTTCGATCCAGCCCCCA 453

QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 215
Db 454 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCGC 488

RESULT 11
LOCUS AR262810 2691 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 1 from patent US 6331388.
ACCESSION AR262810
VERSION AR262810.1 GI:28074512
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2691)
AUTHORS Malkovsky,M. and Wells,A.D.
TITLE Immune response enhancer
JOURNAL Patent: US 6331388-A 1 18-DEC-2001;
FEATURES Location/Qualifiers
source 1..2691
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 100.0%; Score 215; DB 6; Length 2691;
Best Local Similarity 100.0%; Pred. No. 1,1e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTCACTACTTTTCGAGAGTACTCC 60
Db 274 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTCACTACTTTTCGAGAGTACTCC 333

QY 61 GTTGTCCCAAGGCTTCCGAGGAACTGTGGGCTTGAGAGACCGGCGCTCGAGTTT 120
Db 334 GTTGTCCCAAGGCTTCCGAGGAACTGTGGGCTTGAGAGACCGGCGCTCGAGTTT 393

QY 121 CCGGCGTCCGGAAGAGACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180
Db 394 CCGGCGTCCGGAAGAGACCGAGCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 453

QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215
Db 454 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 488

RESULT 12
LOCUS HUMHSP70D 2691 bp DNA linear PRI 08-NOV-1994
DEFINITION Human heat shock protein (hsp 70) gene, complete cds.
ACCESSION M11717 M15432
VERSION M11717.1 GI:184416
KEYWORDS HSP70 gene; heat shock protein.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 2691)
AUTHORS Hunt,C. and Morimoto,R.I.
TITLE Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 82 (19), 6455-6459 (1985)
MEDLINE 86016721
PUBMED 3931075

REFERENCE 2 (bases 94 to 293)
AUTHORS Moryan,W.D., Williams,G.T., Morimoto,R.I., Greene,J., Kingston,R.E. and Tjian,R.
TITLE Two transcriptional activators, CCAAT-box-binding transcription factor and heat shock transcription factor, interact with a human hsp70 gene promoter
JOURNAL Mol. Cell. Biol. 7 (3), 1129-1138 (1987)
MEDLINE 87172780
PUBMED 3561411

COMMENT Original source text: Homo sapiens DNA.
[2] revises [1]. Sequence revised July 30, 1992.
FEATURES Location/Qualifiers
source 1..2691
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21..3"
274..2691
/product="70 kda hsp mRNA"
489..2411
/gene="HSP70"
/note="HSP70"
/note="70 kda"
/codon_start=1
/product="heat shock protein"
/protein_id="AA52697.1"
/db_xref="GI:386785"
/db_xref="GDB:G00-120-058"
/translation="MAKAAVGIDIGTTCYGVGFPHGKVEIIANDQGNRTPSYAF
TDTERLIGDAKNQVAILNPQTVTPAKRLIGKRPDPVYQSMKHPVITNDGKPK
VQVSYKGETKATFPEISISWVLTAKKEIAEALGIPVTAIVITPAIFPDSQRATKD
AGVIAGLVNLRILINEPTAALAYGLDRCKGRNVLIIDLAGGTDFVSLITLIDGLFE
VKATAGDTHLGEDEPNRLVNHVEEFKXKAKDISONKRAVRLRTACERAKRTISS
STQASLEIDSLEGIIDEVTSITRAFPEELCSLPFSTLEPVEKALADAKLDRAQIIDL
VIVGSGSTRIPKVKLIDPFNGRDLNKSINPEAVGYAAVOAAILMGDKSRNVODLL
LIDVAPLSIGLETAGVNTALIKRSTIPTKQTQFTTYSNDQPVLYIYGERAMT
KNNLILGRFELSGLTPPAGVPOIEVTFDIDANGILNVTAITDKSTGKANKITITNDGR
LSKEIIRNVQASAEKAEVQRRVSAKNALSEYAVFMKSAVDEGKAKTISEADK
KKVLDKCEVISMIDANTLAEKDEFEHKKKEILEQVNPILISGLYQAGAGPGRGFGAQ
GPKGSGSGSPFTIEVD"

ORIGIN
Query Match 100.0%; Score 215; DB 9; Length 2691;
Best Local Similarity 100.0%; Pred. No. 1,1e-46;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTCACTACTTTTCGAGAGTACTCC 60
Db 274 ATPACGGCTAGCCTGAGAGCTGCTGCGACATGCTCACTACTTTTCGAGAGTACTCC 333

QY 61 GTTGTCCCAAGGCTTCCGAGGAACTGTGGGCTTGAGAGACCGGCGCTCGAGTTT 120
Db 334 GTTGTCCCAAGGCTTCCGAGGAACTGTGGGCTTGAGAGACCGGCGCTCGAGTTT 393

QY 121 CCGGCGTCCGGAAGAGACCGAGCTTCTTCGCGATTCAGTGTTCGTTTCCAGCCCCCA 180
Db 394 CCGGCGTCCGGAAGAGACCGAGCTTCTTCGCGATTCAGTGTTCGTTTCCAGCCCCCA 453

QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 215
Db 454 TCTCAGAGCCGAGCCGACAGAGAGGAGAACCGC 488

RESULT 13
LOCUS AB018045 4360 bp DNA linear PRI 14-APR-2000
DEFINITION Homo sapiens HSP70-1 gene for heat shock protein 72, spliced variant, partial cds.
ACCESSION AB018045
VERSION AB018045.1 GI:4691417
KEYWORDS HSP70-1; heat shock protein 72; HSP70-Hom; alternative splicing.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (sites)
AUTHORS Shimizu,S., Nomura,K., Ujihara,M. and Demura,H.
TITLE An additional exon of stress-inducible heat shock protein 70 gene (HSP70-1)
JOURNAL Biochem. Res. Commun. 257 (1), 193-198 (1999)
MEDLINE 99194576

PUBMED 10092532
 REFERENCE 2 (bases 1 to 4360)
 AUTHORS Nomura K. and Shimizu S.
 TITLE Direct Submission
 JOURNAL Submitted (27-SEP-1998) Kaoru Nomura, Tokyo Women's Medical University, Department of Medicine 2; 8-1 Kawadacho, Shinjyuku-ku, Tokyo 162-8666, Japan (E-mail:nomura7@parkcity.ne.jp, Tel:81-3-3353-8111(ex 39223), Fax:81-3-3357-6475)
 COMMENT Sequence updated (26-Oct-1998).
 FEATURES
 source
 1..4360
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="6"
 /map="6p21.3"
 gene
 complement(1)..196)
 /gene="HSP70-Hom"
 misc_feature
 complement(1)..196)
 /gene="HSP70-Hom"
 gene
 2323..4360
 /gene="HSP70-1"
 2323..2679
 /gene="HSP70-1"
 /note="alternative splicing"
 CDS
 join(2632..2679,3955..>4360)
 /gene="HSP70-1"
 /note="spliced variant"
 /codon_start=1
 /product="heat shock protein 72"
 /protein_id="BA07235.1"
 /db_xref="GI:4691418"
 /translation="MKHPFQVINDGKPKQVSYKGTNAPYEELISSWLTQKKEI
 AEALGVEYTNAAVITVPAYFNDSDQRAKDGAGVAGLVARIINEPTAAALAYGLDPT
 GKGRNVYIFDLGGTDFVSLITIDDGFEVKATVADPTHLGGEDFDRNQ"
 exon
 3443..3954
 /gene="HSP70-1"
 /note="alternative splicing
 transcription usually starts from exon 2"
 number=2
 3955..>4360
 /gene="HSP70-1"
 /note="alternative splicing"
 number=3
 exon
 3955..>4360
 /gene="HSP70-1"
 /note="alternative splicing"
 number=3
 ORIGIN
 Query Match 100.0%; Score 215; DB 9; Length 4360;
 Best Local Similarity 100.0%; Pred. No. 1,1e-46;
 Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 ATAAAGGCTTAACCTGAGAGAGCTGCTGCAGACAGTCCATCACTTTTTCAGAGTGACTCCC 60
 |||||
 Db 3434 ATAAAGGCTTAACCTGAGAGAGCTGCTGCAGACAGTCCATCACTTTTTCAGAGTGACTCCC 349393
 Oy 61 GTTGTCCCAAGGCTTCCCAAGACCACTGTGCGGCTGACAGACACCGCGCTGCAGATT 120
 |||||
 Db 3494 GTTGTCCCAAGGCTTCCCAAGACCACTGTGCGGCTGACAGACACCGCGCTGCAGATT 355333
 Oy 121 CCGGGTCCGGAAGGACCGAGCTCTTCTCGGGGATCCAGTGTTCGGTTTCCAGCCCCCAA 180
 |||||
 Db 3554 CCGGGTCCGGAAGGACCGAGCTCTTCTCGGGGATCCAGTGTTCGGTTTCCAGCCCCCAA 361333
 Oy 181 TCTCAGAGCCGAGCCGACAGAGAGAGAGGGAACCGC 215
 |||||
 Db 3614 TCTCAGAGCCGAGCCGACAGAGAGAGAGGGAACCGC 3648
 |||||
 RESULT 14
 S52686 488 bp DNA linear PRI 08-MAY-1993
 LOCUS HLA class III polymorphic region: HSP70-1=heat shock protein 70 (5'
 region) [human, PGF, W749, W751, Genomic, 488 nt].

ACCESSION	S52686
VERSION	S52686.1
GI	263578
KEYWORDS	
SOURCE	
ORGANISM	Homo sapiens (human)
REFERENCE	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Cascino,I., Sorrentino,R. and Testi,R.
TITLE	Strong genetic association between HLA-DR3 and a polymorphic variation in the regulatory region of the HSP70-1 gene
JOURNAL	Immunogenetics 37 (3), 177-182 (1993)
MEDLINE	93131289
PUBMED	8420825
REMARK	GenBank staff at the National Library of Medicine created this entry [NCBI gisdbq 12511] from the original journal article.
COMMENT	Region: HLA class III polymorphic region.
FEATURES	Location/Qualifiers
source	1..488
gene	/organism="Homo sapiens"
	/mol_type="genomic DNA"
	/db_xref="taxon:9606"
	1..488
	/gene="HSP70-1"
	/note="heat shock protein 70"
ORIGIN	
Query Match	99.8%; Score 214.6; DB 9; Length 488;
Best Local Similarity	99.5%; Pred. No. 1.6e-46;
Matches 214; Conservative	1; Mismatches 0; Indels 0; Gaps 0;
OY	1 ATAAAGGCTGAGCTGGAGACTGCTCGGACAATCCACTTCTTTGAGAGTGACTCCC 60
Dd	274 ATAAAGGCTGAGCTGGAGACTGCTCGGACAATCCACTTCTTTGAGAGTGACTCCC 333
OY	61 GTTAGTCCCAAGGCTTCCTCAGAGCGAAGCTGTGCAGCGCATCGAGCGCGCTCGAGTTT 120
Dd	334 GTTAGTCCCAAGGCTTCCTCAGAGCGAAGCTGTGCAGCGCATCGAGCGCGCTCGAGTTT 393
OY	121 CCGGCGTCCGGAAGGACCGAGCTCTTCTCGCGATTCCAGTGTTCGTTTTACGCCCAA 180
Dd	394 CCGGCGTCCGGAAGGACCGAGCTCTTCTCGCGATTCCAGTGTTCGTTTTACGCCCAA 453
OY	181 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACGCC 215
Dd	454 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACGCC 488
RESULT 15	
LOCUS	CQ806661 5387 bp DNA linear PAT 10-MAY-2004
DEFINITION	Sequence 111 from Patent WO2004035803.
ACCESSION	CQ806661
VERSION	CQ806661.1
KEYWORDS	GI:47112043
SOURCE	
ORGANISM	Homo sapiens (human)
REFERENCE	Homo sapiens
AUTHORS	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE	Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F., Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and Marx,A.
JOURNAL	Method and nucleic acids for the improved treatment of breast cell proliferative disorders
Patent:	WO 2004035803-A 111 29-APR-2004;
Epigenomics AG (DE)	
location/Qualifiers	
source	1..5387
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
ORIGIN	

Query Match 99.5%; Score 214; DB 6; Length 5387;
 Best Local Similarity 100.0%; Pred. No. 2e-46;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	ATAACGGCTAGCCTGAGAGCTGCTGCCAGTCCACTACTTTTCGAGAGTGACTCCC	60
DB	1982	ATAACGGCTAGCCTGAGAGCTGCTGCCAGTCCACTACTTTTCGAGAGTGACTCCC	2041
QY	61	GTTGTCCCAAGGCTTCCAGAGGSAACCTGTGCGGCTGAGGACCCGGCGTCCAGTTT	120
DB	2042	GTTGTCCCAAGGCTTCCAGAGGSAACCTGTGCGGCTGAGGACCCGGCGTCCAGTTT	2101
QY	121	CCGGCGTCCGGAAGGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCCCA	180
DB	2102	CCGGCGTCCGGAAGGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCCCA	2161
QY	181	TCTCAGAGCCGAGCCGACAGAGACAGGGAACCG	214
DB	2162	TCTCAGAGCCGAGCCGACAGAGACAGGGAACCG	2195

Search completed: February 11, 2005, 08:35:10
 Job time : 1055 secs

This Page Blank (USP10)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 06:52:38 / Search time 221 Seconds
(without alignments)
5759.024 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215
Sequence: 1 ataacgcgtacgtcgtgagag.....gacagagacgcgggaaccgc 215

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: N_Geneseq_16Dec04:*

1: geneeqn19808:*
2: geneeqn19908:*
3: geneeqn20008:*
4: geneeqn2001as:*
5: geneeqn2001bs:*
6: geneeqn2002as:*
7: geneeqn2002bs:*
8: geneeqn2003as:*
9: geneeqn2003bs:*
10: geneeqn2003cs:*
11: geneeqn2003ds:*
12: geneeqn2004as:*
13: geneeqn2004bs:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	215	100.0	215	3	AAA94740	Aaa94740 Human HSP
2	215	100.0	215	3	AAA94756	Aaa94756 Human HSP
3	215	100.0	2691	6	ABA99140	Ab99140 Human hsp
4	215	100.0	2691	6	ABK83917	Abk83917 Human cDN
5	215	100.0	2691	10	ADD14739	Add14739 Human src
6	214	99.5	2732	10	ADD29869	Add29869 Human tum
7	214	99.5	2767	12	ADQ87261	Adq87261 Human tum
8	214	99.5	2767	12	ADQ84979	Adq84979 Human tum
9	214	99.5	2767	13	ADQ83802	Adq83802 Human tum
10	214	99.5	5387	13	ADS89095	Ads89095 Human HSP
11	213.4	99.3	549	9	ADA45212	Ada45212 Human hsp
12	213.4	99.3	2465	2	AAT58086	Aat58086 Human hsp
13	213	99.1	213	12	ADO01084	Ado01084 Human hsp
14	212.4	98.8	2700	3	AAA97541	Aaa97541 Human hsp
15	210.4	97.9	1903	11	ADM02338	Adm02338 Human cDN
16	208.6	97.0	2465	3	AAA15620	Aaa15620 Human hsp
17	195	90.7	2387	12	ADL82938	Adl82938 Human hsp
18	195	90.7	2387	13	ADR25283	Adr25283 Breast ca
19	195	90.7	2387	13	ACN38447	Acn38447 Tumour-as
20	191.4	89.0	2412	12	ADE76979	Ad76979 Human cDN

21	186.8	86.9	2302	3	AAA15622	Aaa15622 Human hsp
22	186.2	86.6	511	4	AAT88560	Aat88560 CNS disor
23	185.2	86.1	2302	3	AAA15621	Aaa15621 Human hsp
24	163.6	76.1	506	12	ACH73362	Ach73362 Human gen
25	163.6	76.1	2876	8	ACA89884	Ac89884 Gene diff
26	156.8	72.9	2458	12	ADE76980	Ad76980 Human cDN
27	156.8	72.9	2513	10	ADD29868	Add29868 Human tum
28	145.2	67.5	595	6	ABQ30839	Abq30839 Oligonuc
29	145.2	67.5	595	6	ABQ30838	Abq30838 Oligonuc
30	145.2	67.5	596	6	ABQ34141	Abq34141 Oligonuc
31	145.2	67.5	596	6	ABQ34140	Abq34140 Oligonuc
32	145.2	67.5	5387	13	ADS89452	Ads89452 Oligonuc
33	145.2	67.5	9899	6	ABL34442	Ab134442 Human imm
34	134	62.3	595	6	ABQ30841	Abq30841 Oligonuc
35	134	62.3	595	6	ABQ30840	Abq30840 Oligonuc
36	134	62.3	596	6	ABQ34139	Abq34139 Oligonuc
37	134	62.3	596	6	ABQ34138	Abq34138 Oligonuc
38	134	62.3	5387	13	ADS89451	Ads89451 Oligonuc
39	134	62.3	9899	6	ABL34443	Ab134443 Human imm
40	116.6	54.2	2460	10	ADF76348	Adf76348 Novel hum
41	116.6	54.2	2460	12	ADO87260	Ado87260 Human tum
42	116.6	54.2	2460	12	ADO83801	Ado83801 Human tum
43	116.6	54.2	2460	13	ADQ84978	Adq84978 Human tum
44	116.6	54.2	2460	13	ACN38446	Acn38446 Tumour-as
45	113.8	52.9	5387	13	ADS89726	Ads89726 Oligonuc

ALIGNMENTS

RESULT 1

AAA94740
ID AAA94740 standard; DNA; 215 BP.

XX AAA94740;

XX 19-JAN-2001 (first entry)

XX Human HSP70A 5' untranslated region DNA sequence.

XX Human; HSP70A, 5' UTR; untranslated region; heat shock protein;

XX translation efficiency; vaccine; bacterial; viral; parasitic infection;

XX immune-related disease; contraceptive; gene therapy; cancer;

XX cardiovascular disorder; cystic fibrosis; de.

XX Homo sapiens.

XX WO200053785-A2.

XX 14-SEP-2000.

XX 09-MAR-2000; 2000WO-EP002031.

XX 11-MAR-1999; 99GB-00005498.

XX (GLAXO) GLAXO GROUP LTD.

XX Coste HJ, Ellis JH;

XX WPI; 2000-594331/56.

XX Human heat shock protein 5' untranslated region (UTR) transcribed to

XX provide an RNA molecule having UTR that increases translation efficiency

XX of polypeptides, useful for treating deficiency in expression of the

XX polypeptide.

XX Claim 7, Page 28; 44pp; English.

XX The present sequence is the 5' untranslated region (UTR) of human heat

XX shock protein (Hsp) 70A gene. This sequence has a high potential to form

XX secondary structures. This sequence can be used to increase the

XX translation efficiency of a polypeptide. The present sequence may be

XX useful in therapeutic or prophylactic vaccination for preventing

The present sequence is the 5' untranslated region (UTR) mRNA of human heat shock protein (Hsp) 70a gene. This sequence has a high potential to form secondary structures. This sequence can be used to increase the translation efficiency of a polypeptide. The present sequence may be useful in therapeutic or prophylactic vaccination for preventing bacterial, viral and parasitic infections and also for treating immune-related diseases and for contraceptive purposes. In addition, the present

This invention relates to increasing expression of an MHC class I molecule in a target cell, infected with a pathogen that is processed by the MHC class I endogenous pathway. The method of expressing a HSP is achieved by the introduction of an expression vector encoding HSP to produce a transfected cell with increased expression of at least one MHC class I molecule. The method is cytostatic, antibacterial and antiparasitic. The method can be used to increase expression of an MHC class I molecule in a target cell and to increase presentation of an antigen on a cell surface by an MHC class I molecule. The method can enhance the immunogenicity of the endogenous antigen *in vivo*, by enhancing the generation of antibodies to an otherwise poorly immunogenic

CC antigen or cell. The method can be used in the immunotherapy of cancer
CC and pathogen infections, and for enhancing or reducing radiation
CC resistance of cells. The expression of the heat shock protein in a cell
CC enhances the presentation of endogenous antigens by MHC class I molecules
CC onto the cell surface in vitro, and can enhance the immunogenicity of the
CC endogenous antigen in vivo, by enhancing the generation of antibodies to
CC the otherwise poorly immunogenic antigen or cell. This sequence represents
CC the cDNA of human hsp72

Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;

Query Match 100.0%; Score 215; DB 6; Length 2691;
Best Local Similarity 100.0%; Pred. No. 1.1e-54;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGCGCTAGCGCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTACTCC 60
DB 274 ATAAAGCGCTAGCGCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTACTCC 333
QY 61 GTTGTCCAGAGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGCGCTGAGATT 120
DB 334 GTTGTCCAGAGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGCGCTGAGATT 393
QY 121 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCACTGTTCCGTTCCAGCCCCCA 180
DB 394 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCACTGTTCCGTTCCAGCCCCCA 453
QY 181 TCTCAGAGCCGAGCCGAGAGGAGGAGGACCGC 215
DB 454 TCTCAGAGCCGAGCCGAGAGGAGGAGGACCGC 488

RESULT 4

ABK83917 standard; cDNA; 2691 BP.

ID ABK83917

AC ABK83917;

DT 14-AUG-2002 (first entry)

DE Human cDNA differentially expressed in granulocytic cells #488.
XX
XX Human; ss; granulocytic cell; DNA chip; bacterial infection;
KW viral infection; parasitic infection; protozoal infection;
KW fungal infection; sterile inflammatory disease; psoriasis;
KW rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW adult respiratory distress syndrome; inflammatory bowel disease;
KW Crohn's disease; ulcerative colitis; periodontal disease;
KW granulocyte activation; chronic inflammation; allergy.

OS Homo sapiens.

PN WO200228999-A2.

PD 11-APR-2002.

XX 03-OCT-2001; 2001WO-US030821.

PR 03-OCT-2000; 2000US-0237189P.

XX (GENE-) GENE LOGIC INC.

PA Beazer-Barclay Y, Weisman SM, Yamaga S, Vockley J;

PI WPI; 2002-435328/46.

DR Detecting granulocyte activation by detecting differential expression of
XX PT genes associated with granulocyte activation, which serves as diagnostic
XX PT markers that is useful for monitoring disease states and drug toxicity.
XX Claim 1; SEQ ID NO 488; 114pp; English.

CC The invention relates to detecting (M1) granulocyte (GC) activation
CC (GCM), by detecting the level of expression of gene(s) (Gs) identified by
CC DNA chip analysis as given in the specification, and comparing the
CC expression level to an expression level in an unactivated GC, where
CC differential expression of Gs is indicative of GCM. Also included are
CC modulating (M2) GC by contacting GC with an agent that alters the
CC expression of at least one gene in Gs; (2) screening (M3) for an agent
CC capable of modulating GCM or an inflammation (especially chronic) in a
CC tissue, an allergic response in a subject, exposure of a subject to a
CC pathogen or sterile inflammatory disease using the gene expression
CC profile; (3) detecting (M4) an inflammation (especially chronic) in a
CC tissue, an allergic response in a subject, exposure of a subject to a
CC pathogen or sterile inflammatory disease, by detecting the level of
CC expression in a sample of the tissue of gene(s) from Gs, where the level
CC of expression of the gene is indicative of inflammation; (4) treating
CC (M5) an inflammation (especially chronic) or in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease, by contacting a tissue having inflammation with an
CC agent that modulates the expression of gene(s) from Gs in the tissue. M1
CC is useful for detecting GCM; M2 is useful for modulating GCM; M3 is useful
CC for screening an agent capable of modulating GCM preferably in an
CC inflammation in a tissue; M4 is useful for detecting an inflammation
CC (especially chronic) in a tissue, an allergic response in a subject,
CC exposure of a subject to a pathogen or sterile inflammatory disease (e.g.
CC psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, thrombosis,
CC cardiac reperfusion injury, renal reperfusion injury, ARDS, adult
CC respiratory distress syndrome, inflammatory bowel disease, Crohn's
CC disease, ulcerative colitis, periodontal disease; also bacterial
CC infection, viral infection, parasitic infection, protozoal infection,
CC fungal infection and M5 is useful for treating one of the above
CC conditions. The present sequence represents a gene differentially
CC expressed in granulocytes. Note: The sequence data for this patent did
CC not form part of the printed specification, but was obtained in
CC electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;

Query Match 100.0%; Score 215; DB 6; Length 2691;
Best Local Similarity 100.0%; Pred. No. 1.1e-54;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGCGCTAGCGCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTACTCC 60
DB 274 ATAAAGCGCTAGCGCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTACTCC 333
QY 61 GTTGTCCAGAGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGCGCTGAGATT 120
DB 334 GTTGTCCAGAGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGCGCTGAGATT 393
QY 121 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCACTGTTCCGTTCCAGCCCCCA 180
DB 394 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATCACTGTTCCGTTCCAGCCCCCA 453
QY 181 TCTCAGAGCCGAGCCGAGAGGAGGAGGACCGC 215
DB 454 TCTCAGAGCCGAGCCGAGAGGAGGAGGACCGC 488

RESULT 5

ADD14739 standard; cDNA; 2691 BP.

ID ADD14739

AC ADD14739;

DT 01-JAN-2004 (first entry)

DE Human src biomarker polynucleotide SEQ ID NO:133.
XX
XX predictor set, protein tyrosine kinase activity modulator;
KW protein tyrosine kinase pathway; protein tyrosine kinase; cytosolic;
KW gene therapy; drug sensitivity; genetic profile; cancer; human; gene; ss.

OS Homo sapiens.
 XX WO2003062395-A2.
 XX 31-JUL-2003.
 PD 17-JAN-2003, 2003WO-US001981.
 XX 17-JAN-2003, 2003WO-US001981.
 XX 18-JAN-2002, 2002US-0350061P.
 XX (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA
 XX Huang F, Faichild CR, Lee FY, Shaw P,
 PI WPI, 2003-636735/60.
 DR P-PSDB; ADD14137.
 XX
 PT New polynucleotides and polypeptides for predicting the activity of
 PT compounds that interact with protein tyrosine kinases and/or protein
 PT tyrosine kinase pathways.
 PS
 XX Claim 2; SEQ ID NO 133; 139pp; English.
 CC The present invention describes a predictor set comprising a plurality of
 CC polynucleotides or polypeptides whose expression pattern is predictive of
 CC the response of cells to treatment with a compound that modulates protein
 CC tyrosine kinase activity or members of the protein tyrosine kinase
 CC pathway. Also described: (1) predicting whether a compound is capable of
 CC modulating the activity of cells, comprising obtaining a sample of cells,
 CC determining whether the cells express a plurality of markers, and
 CC correlating the expression of the markers to the compound's ability to
 CC modulate the activity of the cells; (2) a plurality of cell lines for
 CC identifying polynucleotides and polypeptides whose expression levels
 CC correlate with compound sensitivity or resistance of cells associated
 CC with a disease state; and (3) identifying polynucleotides and
 CC polypeptides that predict compound sensitivity or resistance of cells
 CC associated with a disease state, comprising subjecting the plurality of
 CC cell lines to one or more compounds, analysing the expression pattern of
 CC a microarray of polynucleotides or polypeptides, and selecting
 CC polynucleotides or polypeptides that predict the sensitivity or
 CC resistance of cells associated with a disease state by using the
 CC expression pattern of the microarray. The polynucleotides and
 CC polypeptides have cytostatic activities, and can be used in gene therapy.
 CC The polynucleotides and polypeptides are useful in predicting the
 CC activity of compounds that interact with protein tyrosine kinases and/or
 CC protein tyrosine kinase pathways. These may be used in determining drug
 CC sensitivity in patients to allow the development of individualized
 CC genetic profiles which aid in treating diseases and disorders (e.g.
 CC cancer) based on patient response at a molecular level. The present
 CC sequence is used in the exemplification of the present invention.
 SQ Sequence 2691 BP; 600 A; 780 C; 831 G; 480 T; 0 U; 0 Other;
 Query Match 100.0%; Score 215; DB 10; Length 2691;
 Best Local Similarity 100.0%; Pred. No. 1.1e-54;
 Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 60
 DB 274 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 333
 QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGGTGGAGGACCGGGCGCTCGAGTTT 120
 DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGGTGGAGGACCGGGCGCTCGAGTTT 393
 QY 121 CGGGGCTCCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 180
 DB 394 CGGGGCTCCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 453
 QY 181 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCGC 215
 DB 454 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCGC 488

RESULT 6
 ADD29869
 ID ADD29869 standard; mRNA; 2732 BP.
 XX
 XX ADD29869;
 AC
 XX 15-JAN-2004 (first entry)
 DT
 XX Human tumour suppressor mRNA SEQ ID NO:300.
 DE
 XX ss; human; tumour suppressor; cancer; cancer; cytostatic; gene therapy.
 KW
 XX
 OS Homo sapiens.
 XX
 XX WO2003058201-A2.
 XX 17-JUL-2003.
 PD 31-DEC-2002; 2002WO-US041825.
 XX 31-DEC-2002; 2002WO-US041825.
 XX 31-DEC-2001; 2001US-0345317P.
 XX (QUNR-) QUNAR BIOTECH INC.
 PA (CLEV-) CLEVELAND CLINIC FOUND.
 PI Feinstein B, Gudkov AV;
 DR WPI, 2003-598393/56.
 XX
 PT Diagnosing cancer comprises determining the polypeptide or polynucleotide
 PT levels e.g., hepatic lipase, in a sample from a subject, where a higher
 PT level compared to that in a subject free of cancer is indicative of
 PT cancer.
 PS Disclosure; SEQ ID NO 300; 272pp; English.
 XX
 CC The invention relates to a novel method for diagnosing a cancer in a
 CC subject, the method comprises determining, in a sample from the subject,
 CC the level of at least one polypeptide, where a higher level of the
 CC polypeptide compared to the level of the polypeptide in a subject free of
 CC cancer is indicative of cancer. The polypeptide is selected from any of
 CC the polypeptides encoded by the polynucleotides listed in the
 CC specification and polypeptides which are at least 70% homologous to the
 CC polypeptides. The method of the invention has cytostatic activity, and
 CC may have a use in gene therapy. The method is useful in identifying
 CC markers specific for one or several types of cancer, depending on the
 CC tissue origin, which may be used in numerous diagnostic and prognostic
 CC applications as well as cancer type-specific targets for therapeutic
 CC intervention. The compounds that modulate the activity of a tumour
 CC suppressor gene are useful in the treatment of cancer or as anti-cancer
 CC drugs. The present sequence represents a polynucleotide of the invention.
 SQ Sequence 2732 BP; 608 A; 787 C; 840 G; 497 T; 0 U; 0 Other;
 Query Match 99.5%; Score 214; DB 10; Length 2732;
 Best Local Similarity 100.0%; Pred. No. 2.3e-54;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 60
 DB 274 ATAAAGGCTAGGCTGAGAGCTGTCGACAGTCACTCACTTTTTCGAGAGTACTCCC 333
 QY 61 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGGTGGAGGACCGGGCGCTCGAGTTT 120
 DB 334 GTTGTCCCAAGGCTTCCAGAGGAACTGTGGGGTGGAGGACCGGGCGCTCGAGTTT 393
 QY 121 CGGGGCTCCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 180
 DB 394 CGGGGCTCCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 453
 QY 181 TCTCAGAGCCGAGCCGACAGAGAGCGGAAACCG 214

DB 454 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 487

RESULT 7

ADQ87261 ID ADQ87261 standard; cDNA; 2767 BP.

AC ADQ87261;

XX 07-OCT-2004 (first entry)

DT

XX Human tumour-associated antigenic target (TAT) cDNA sequence #4138.

DE human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;

XX human; cell proliferative disorder; gene; ss.

XX Homo sapiens.

OS WO2004060270-A2.

PN 22-JUL-2004.

XX 15-OCT-2003; 2003WO-US029126.

XX 18-OCT-2002; 2002US-0418988P.

PR (GENTH) GENENTECH INC.

XX (WUTD/) WU T D.

XX (ZHOU/) ZHOU Y.

PA Wu TD, Zhou Y;

PI MPI; 2004-534300/51.

DR New nucleic acid molecule and encoded polypeptide, for diagnosing,

PT preventing or treating cell proliferative disorders such as cancer.

XX Claim 1, SEQ ID NO 4138; 5504bp; English.

XX The present invention describes an isolated tumour-associated antigenic

CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide

CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of

CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%

CC sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-

CC (c). Also described: (1) an expression vector comprising the above

CC nucleic acid; (2) a host cell comprising the above expression vector; (3)

CC a process for producing a polypeptide; (4) an isolated polypeptide

CC comprising: (a) an amino acid sequence encoded by any of the above

CC nucleotide sequences; (b) an amino acid sequence encoded by the full-

CC length coding region of the above nucleotide sequences; or (c) a sequence

CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide

CC comprising the above polypeptide fused to a heterologous polypeptide; (6)

CC an isolated antibody that binds to the above polypeptide; (7) a process

CC for producing the antibody; (8) an isolated oligopeptide that binds to

CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)

CC binding organic molecule that binds to the above polypeptide; (10) a

CC composition of matter comprising the above (chimeric) polypeptide,

CC antibody, oligopeptide or TAT binding organic molecule, in combination

CC with a carrier; (11) an article of manufacture comprising a container and

CC the composition of matter contained within the container; (12) methods of

CC inhibiting the growth of a cell that expresses the above protein, where

CC the growth of the cell is at least in part dependent upon a growth

CC potentiating effect of the above protein; (13) a method of

CC therapeutically treating a mammal having a cancerous tumour comprising

CC cells that express the above protein; (14) a method of determining the

CC presence of a protein in a sample suspected of containing the protein

CC described above; (15) methods of diagnosing the presence of a tumour in a

CC mammal; (16) a method for treating or preventing a cell proliferative

CC disorder associated with increased expression or activity of the above

CC protein; and (17) a method of binding an antibody, oligopeptide or

CC organic molecule to a cell that expresses the protein described above.

CC The TAT sequences have cytostatic activities, and can be used in gene

CC therapy. The composition and methods are useful for diagnosing,

CC preventing or treating cancer. The composition is also used for preparing

CC a medicament for the therapeutic treatment or diagnostic detection of a

CC cell proliferative disorder or cancer. The present sequence represents a

CC human TAT cDNA sequence from the present invention.

XX SQ Sequence 2767 BP; 621 A; 808 C; 854 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 12; Length 2767;

Best Local Similarity 100.0%; Pred. No. 2,3e-54;

Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATPACGGCTAGCCTTAGAGCTGCTGCGACAGTCACTACTTTTTCGAGAGTACTCCC 60

DB 362 ATPACGGCTAGCCTTAGAGCTGCTGCGACAGTCACTACTTTTTCGAGAGTACTCCC 421

QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACCCTGTGCGCTGACGACCGGCGCTCGAGTTT 120

DB 422 GTTGTCCCAAGGCTTCCAGAGCGAACCCTGTGCGCTGACGACCGGCGCTCGAGTTT 481

QY 121 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATTCAGTGTTCGATCCGCCCA 180

DB 482 CCGGCGTCCGGAAGACCGAGCTCTTCTGCGGATTCAGTGTTCGATCCGCCCA 541

QY 181 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 214

DB 542 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 575

RESULT 8

ADQ84979 ID ADQ84979 standard; cDNA; 2767 BP.

XX ADQ84979;

XX 07-OCT-2004 (first entry)

DT

XX Human tumour-associated antigenic target (TAT) cDNA sequence #1793.

DE human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;

XX human; cell proliferative disorder; gene; ss.

XX Homo sapiens.

OS WO2004060270-A2.

PN 22-JUL-2004.

XX 15-OCT-2003; 2003WO-US029126.

XX 18-OCT-2002; 2002US-0418988P.

PR (GENTH) GENENTECH INC.

XX (WUTD/) WU T D.

XX (ZHOU/) ZHOU Y.

PA Wu TD, Zhou Y;

PI MPI; 2004-534300/51.

DR New nucleic acid molecule and encoded polypeptide, for diagnosing,

PT preventing or treating cell proliferative disorders such as cancer.

XX Claim 1, SEQ ID NO 1793; 5504bp; English.

XX The present invention describes an isolated tumour-associated antigenic

CC target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide

CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of

CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%

CC sequence identity to (a)-(c); or (e) a sequence that hybridises to (a)-

CC (c). Also described: (1) an expression vector comprising the above

CC nucleic acid; (2) a host cell comprising the above expression vector; (3)

CC a process for producing a polypeptide; (4) an isolated polypeptide

CC comprising: (a) an amino acid sequence encoded by any of the above

CC nucleotide sequences; (b) an amino acid sequence encoded by the full-
 CC length coding region of the above nucleotide sequences; or (c) a sequence
 CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide
 CC comprising the above polypeptide fused to a heterologous polypeptide; (6)
 CC an isolated antibody that binds to the above polypeptide; (7) a process
 CC for producing the antibody; (8) an isolated oligopeptide that binds to
 CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)
 CC binding organic molecule that binds to the above polypeptide; (10) a
 CC composition of matter comprising the above (chimeric) polypeptide,
 CC antibody, oligopeptide or TAT binding organic molecule, in combination
 CC with a carrier; (11) an article of manufacture comprising a container and
 CC the composition of matter contained within the container; (12) methods of
 CC inhibiting the growth of a cell that expresses the above protein, where
 CC the growth of the cell is at least in part dependent upon a growth
 CC potentiating effect of the above protein; (13) a method of
 CC therapeutically treating a mammal having a cancerous tumour comprising
 CC cells that express the above protein; (14) a method of determining the
 CC presence of a protein in a sample suspected of containing the protein in a
 CC described above; (15) methods of diagnosing the presence of a tumour in a
 CC mammal; (16) a method for treating or preventing a cell proliferative
 CC disorder associated with increased expression or activity of the above
 CC protein; and (17) a method of binding an antibody, oligopeptide or
 CC organic molecule to a cell that expresses the protein described above.
 CC The TAT sequences have cytostatic activities, and can be used in gene
 CC therapy. The composition and methods are useful for diagnosing,
 CC preventing or treating cancer. The composition is also used for preparing
 CC a medicament for the therapeutic treatment or diagnostic detection of a
 CC cell proliferative disorder or cancer. The present sequence represents a
 CC human TAT cDNA sequence from the present invention.

SO Sequence 2767 BP; 621 A; 809 C; 853 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 12; Length 2767;
 Best Local Similarity 100.0%; Pred. No. 2,3e-54;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAACGGCTAGCCTGAGAGAGCTGCTGCGACAGCTCACTCTTTTCAGAGTGAATCCC 60
 DB 362 ATAAACGGCTAGCCTGAGAGAGCTGCTGCGACAGCTCACTCTTTTCAGAGTGAATCCC 421
 QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
 DB 422 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 481
 QY 121 CCGGCGTCCGGAAGAGCCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180
 DB 482 CCGGCGTCCGGAAGAGCCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 541
 QY 181 TCTCAGAGCCGAGCCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 214
 DB 542 TCTCAGAGCCGAGCCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 575

RESULT 9

AD083802 ID AD083802 standard; cDNA, 2767 BP.

AD083802; 07-OCT-2004 (first entry)

Human tumour-associated antigenic target (TAT) cDNA sequence #616.

human; tumour-associated antigenic target; TAT; cytostatic; gene therapy;
 cancer; cell proliferative disorder; gene; ss.

Homo sapiens.

WO2004060270-A2.

22-JUL-2004.

15-OCT-2003; 2003WO-US029126.

XX 18-OCT-2002; 2002US-0418988P.
 PR (GENENTECH INC.
 XX (GENENTECH INC.
 PA (WU T D.
 PA (ZHOU) ZHOU Y.
 XX Wu TD, Zhou Y;
 PI WPI; 2004-534300/51.
 DR New nucleic acid molecule and encoded polypeptide, for diagnosing,
 PT preventing or treating cell proliferative disorders such as cancer.
 PS Claim 1; SEQ ID NO 616; 5504pp; English.

The present invention describes an isolated tumour-associated antigenic
 target (TAT) nucleic acid comprising: (a) any of 4622 nucleotide
 CC sequences (see SEQ ID NO:1 to 4622); (b) the full-length coding region of
 CC (a); (c) the complement of (a) or (b); (d) a sequence that has 80%
 CC sequence identity to (a)-(c); or (e) a sequence that hybridizes to (a)-
 CC (c). Also described: (1) an expression vector comprising the above
 CC nucleic acid; (2) a host cell comprising the above expression vector; (3)
 CC a process for producing a polypeptide; (4) an isolated polypeptide
 CC comprising: (a) an amino acid sequence encoded by any of the above
 CC nucleotide sequences; (b) an amino acid sequence encoded by the full-
 CC length coding region of the above nucleotide sequences; or (c) a sequence
 CC having at least 80% identical to (a) or (b); (5) a chimeric polypeptide
 CC comprising the above polypeptide fused to a heterologous polypeptide; (6)
 CC an isolated antibody that binds to the above polypeptide; (7) a process
 CC for producing the antibody; (8) an isolated oligopeptide that binds to
 CC the above polypeptide; (9) a tumour-associated antigenic target (TAT)
 CC binding organic molecule that binds to the above polypeptide; (10) a
 CC composition of matter comprising the above (chimeric) polypeptide,
 CC antibody, oligopeptide or TAT binding organic molecule, in combination
 CC with a carrier; (11) an article of manufacture comprising a container and
 CC the composition of matter contained within the container; (12) methods of
 CC inhibiting the growth of a cell that expresses the above protein, where
 CC the growth of the cell is at least in part dependent upon a growth
 CC potentiating effect of the above protein; (13) a method of
 CC therapeutically treating a mammal having a cancerous tumour comprising
 CC cells that express the above protein; (14) a method of determining the
 CC presence of a protein in a sample suspected of containing the protein in a
 CC described above; (15) methods of diagnosing the presence of a tumour in a
 CC mammal; (16) a method for treating or preventing a cell proliferative
 CC disorder associated with increased expression or activity of the above
 CC protein; and (17) a method of binding an antibody, oligopeptide or
 CC organic molecule to a cell that expresses the protein described above.
 CC The TAT sequences have cytostatic activities, and can be used in gene
 CC therapy. The composition and methods are useful for diagnosing,
 CC preventing or treating cancer. The composition is also used for preparing
 CC a medicament for the therapeutic treatment or diagnostic detection of a
 CC cell proliferative disorder or cancer. The present sequence represents a
 CC human TAT cDNA sequence from the present invention.

SO Sequence 2767 BP; 621 A; 808 C; 854 G; 484 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 13; Length 2767;
 Best Local Similarity 100.0%; Pred. No. 2,3e-54;
 Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAACGGCTAGCCTGAGAGAGCTGCTGCGACAGCTCACTCTTTTCAGAGTGAATCCC 60
 DB 362 ATAAACGGCTAGCCTGAGAGAGCTGCTGCGACAGCTCACTCTTTTCAGAGTGAATCCC 421
 QY 61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
 DB 422 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 481
 QY 121 CCGGCGTCCGGAAGAGCCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 180
 DB 482 CCGGCGTCCGGAAGAGCCGAGCTCTTCTCGCGGATCCAGTGTTCGTTTCCAGCCCCCA 541

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCG 214
Db 542 TCTCAGAGCCGAGCCGAGAGAGGAGGAAACCG 575

RESULT 10
ID ADS89095 standard; DNA; 5387 BP.
XX
AC ADS89095;
XX
DT 18-NOV-2004 (first entry)
XX
DE Human HSPA1A gene SEQ ID NO:111.
XX

XX ds; gene; human; cell proliferative disorder; breast; methylation;
KM cytosolic; gene therapy; single nucleotide polymorphism; SNP.
XX
OS Homo sapiens.
XX
PN WO2004035803-A2.
XX
PD 29-APR-2004.
XX
PF 01-OCT-2003; 2003WO-EP010881.
XX
PR 01-OCT-2002; 2002DE-01045779.
PR 07-JAN-2003; 2003DE-01000096.
PR 17-APR-2003; 2003DE-01017955.
XX
PA (EPIG-) EPIGENOMICS AG.
XX

PI Fockens J, Harbeck N, Koenig T, Maier S, Martens J, Model F,
PI Nimrich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;
XX
DR WPI; 2004-348468/32.
XX

PT Predicting responsiveness of a subject with breast cell proliferative
PT disorder, useful for treating or differentiating breast cell
PT proliferative disorders comprises analyzing methylation pattern of a
PT genomic DNA from the subject.
XX
PS Example 2; SEQ ID NO 111; 104pp; English.
XX

CC The invention relates to a novel method for predicting the responsiveness
CC of a subject with a cell proliferative disorder of the breast tissues to
CC a therapy comprising analysing the methylation pattern of a target
CC nucleic acid by contacting at least one of the target nucleic acids in a
CC biological sample obtained from the subject prior to or during treatment.
CC The method of the invention has cytosolic activity, and may have a use
CC in gene therapy. The set of oligonucleotides comprising at least two of
CC the oligomers are useful for detecting the cytosine methylation state
CC and/or single nucleotide polymorphisms (SNPs) within the sequences. The
CC methods, nucleic acid, oligonucleotide, and kit are useful for the
CC treatment, characterisation, classification and/or differentiation, of
CC breast cell proliferative disorders. The method is also useful for
CC predicting the responsiveness of a subject with a cell proliferative
CC disorder of the breast tissues to a therapy. The present sequence is used
CC in the exemplification of the invention.
XX
SQ Sequence 5387 BP; 1291 A; 1506 C; 1471 G; 1119 T; 0 U; 0 Other;

Query Match 99.5%; Score 214; DB 13; Length 5387;
Best Local Similarity 100.0%; Pred. No. 2.7e-54;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATAAAGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60
Db 1982 ATAAAGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 2041
Qy 61 GTTGTCCTCAAGGCTTCCAGAGCGAACTGTGTGGGTGAGGACCGGCGCTCGAGTTT 120
Db 2042 GTTGTCCTCAAGGCTTCCAGAGCGAACTGTGTGGGTGAGGACCGGCGCTCGAGTTT 2101

Qy 121 CCGGCGTCCGGAAGAGACCGAGCTCTTCGCGGATCCAGTGTCCGTTTCCAGCCCCCA 180
Db 2102 CCGGCGTCCGGAAGAGACCGAGCTCTTCGCGGATCCAGTGTCCGTTTCCAGCCCCCA 2161

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCG 214
Db 2162 TCTCAGAGCCGAGCCGACAGAGAGGAGGAAACCG 2195

RESULT 11
ID ADA45212 standard; DNA; 549 BP.
XX
AC ADA45212;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human hsp70 gene 5' promoter region.
XX
XX gene; ds; human; tumour mass; cancer; bone marrow;
KM endothelial cell precursor; ECP; cytosolic;
KM tumour angiogenesis inhibitor; gene therapy; cell therapy; angiogenesis;
KM hsp70; promoter.
XX
OS Homo sapiens.
XX
PN WO2003061591-A2.
XX
PD 31-JUL-2003.
XX
PF 22-JAN-2003; 2003WO-US001827.
XX
PR 22-JAN-2002; 2002US-0349345P.
XX
PA (ADCE-) ADVANCED CELL TECHNOLOGY INC.
XX

PI West MD;
XX
DR WPI; 2003-598707/56.
XX
PT Decreasing tumor mass in a patient comprises grafting genetically
PT modified endothelial cell precursors into the patient.
XX
PS Example 3; Fig 1; 34pp; English.
XX

CC The invention relates to a novel method for decreasing tumour mass in a
CC cancer patient. The method comprises ablating bone marrow from the
CC patient and grafting endothelial cell precursors (ECPs), or their
CC precursors, into the patient such that a decrease in tumour mass results,
CC where the ECPs or their precursors are genetically modified to mediate a
CC decrease in tumour mass. The method of the invention has cytosolic
CC activity. A polynucleotide of the invention acts as a tumour angiogenesis
CC inhibitor, and may have a use in gene therapy and cell therapy.
CC Genetically modified endothelial cell precursors are useful for
CC decreasing tumour mass in a cancer patient. This is particularly useful
CC for inhibiting and/or disrupting angiogenesis of the tumours, and
CC consequently inhibiting tumour growth and killing tumour cells. The
CC present sequence represents the 5' promoter region of the human hsp70
CC gene.
XX
SQ Sequence 549 BP; 110 A; 174 C; 167 G; 98 T; 0 U; 0 Other;

Query Match 99.3%; Score 213.4; DB 9; Length 549;
Best Local Similarity 99.5%; Pred. No. 2.4e-54;
Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 ATAAAGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60
Db 269 ATAAAGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 328
Qy 61 GTTGTCCTCAAGGCTTCCAGAGCGAACTGTGTGGGTGAGGACCGGCGCTCGAGTTT 120


```

Db      339 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGCAGGACCGCGCGCTCGAGTTT 388
Qy      121 CCGGCGTCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 180
Db      369 CCGGCGTCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 448
Qy      181 TCTCAGAGCCGAGCCGAGCAGAGAGCGGAAACCGC 215
Db      449 TCTCAGAGCCGAGCCGAGCAGAGAGCGGAAACCGC 483

RESULT 12
AAT58086
ID      AAT58086 standard; cDNA; 2465 BP.
XX
XX      AAT58086;
XX
XX      24-OCT-1997 (first entry)
XX
XX      Human heat shock protein 70 cDNA.
XX
XX      Human heat shock protein 70; HSP70; primer; probe; detection;
XX      intracellular; abnormal transcription; acute; chronic; sustained; stress;
XX      ss.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
XX      CDS      263..2185
XX      FT      /tag="a "HSP70"
XX      FT      /product="HSP70"
XX
XX      JP08322577-A.
XX
XX      10-DEC-1996.
XX
XX      01-JUN-1995; 95JP-00158581.
XX
XX      01-JUN-1995; 95JP-00158581.
XX
XX      (HOKE-) HOKEN KAGAKU KENRYUSHO KK.
XX
XX      WPI; 1997-081088/08.
XX      P-PSDB; AAW10065.
XX
XX      Detection of abnormal transcription of HSP70 mRNA - using HSP70 specific
XX      primer or probe, used in detection of human acute and chronic sustained
XX      stress load.
XX
XX      Claim 1; Fig 1; 13pp; Japanese.
XX
XX      The present sequence, which encodes human heat shock protein 70 (HSP70),
XX      is located on human chromosome 6p 21.3-22 and 14q 22-24 and 21. Primers
XX      and probes based on the HSP70 cDNA coding sequence can be used to detect
XX      the abnormal transcription of intracellular HSP70 mRNA in human acute and
XX      chronic sustained stress load
XX
XX      Sequence 2465 BP; 553 A; 713 C; 758 G; 441 T; 0 U; 0 Other;
SQ
Query Match      99.3%; Score 213.4; DB 2; Length 2465;
Beet Local Similarity 99.5%; Pred. No. 3.4e-54;
Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy      1 AATAAGGCTAGGCTGAGAGCTGCTGCAAGTCACTACCTTTTCGAGAGTGAATCCC 60
Db      48 AATAAGGCTAGGCTGAGAGCTGCTGCAAGTCACTACCTTTTCGAGAGTGAATCCC 107
Qy      61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGCAGGACCGCGCGCTCGAGTTT 120
Db      108 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGCAGGACCGCGCGCTCGAGTTT 167
Qy      121 CCGGCGTCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 180

```

```

Db      168 CCGGCGTCGGAAGAGCCGAGCTCTTTCGCGGATTCAGTGTTCGTTTCCAGCCCCCA 227
Qy      181 TCTCAGAGCCGAGCCGAGCAGAGAGCGGAAACCGC 215
Db      228 TCTCAGAGCCGAGCCGAGCAGAGAGCGGAAACCGC 262

RESULT 13
AD001084
ID      AD001084 standard; DNA; 213 BP.
XX
XX      AD001084;
XX
XX      29-JUL-2004 (first entry)
XX
XX      Human hsp70 translational enhancer element DNA sequence SEQ ID NO:6.
XX
XX      Increasing glycogen; toxic; toxic glycogen level; glycogen;
XX      cell proliferative disorder; tumour therapy; anti-tumour therapy;
XX      anti-cell proliferative; cytostatic; gene therapy; sarcoma; melanoma;
XX      myeloma; blastoma; glioma; lymphoma; leukaemia; human;
XX      heat shock protein 70; chromosome 6; hsp70; gene; ds.
XX
XX      Homo sapiens.
XX
XX      WO2004039412-A2.
XX
XX      13-MAY-2004.
XX
XX      29-OCT-2003; 2003MO-1B005562.
XX
XX      29-OCT-2002; 2002US-0422365P.
XX
XX      (ENGGE-) ENGGENE INC.
XX
XX      Doiron B, Pownall S, Cheung A, Hsu E;
XX      WPI; 2004-376072/35.
XX      GENBANK; M11717.
XX
XX      Increasing glycogen to toxic levels in a cell, useful for treating cell
XX      proliferative disorder, comprises expressing in a cell a gene product
XX      that increases the amount of glycogen to toxic levels in the cell.
XX
XX      Example 1; SEQ ID NO 6; 98pp; English.
XX
XX      The present invention describes a method for increasing glycogen to toxic
XX      levels in a cell. The method comprises expressing in a cell a gene
XX      product that increases the amount of glycogen to toxic levels in the
XX      cell. Also described: (1) treating a cell proliferative disorder in a
XX      subject, where the cell proliferative disorder is not a liver, muscle or
XX      brain cell disorder, by expressing in one or more cells comprising the
XX      disorder a gene product that increases the amount of intracellular
XX      glycogen, or contacting one or more cells comprising the disorder with an
XX      agent that increases the amount of intracellular glycogen, sufficient to
XX      treat the cell proliferative disorder; (2) treating a subject that is
XX      undergoing or has undergone tumour therapy, where the tumour therapy was
XX      not for liver, muscle or brain tumour by administering to the subject an
XX      agent in an amount that increases the amount of intracellular glycogen in
XX      a cell; (3) increasing effectiveness of an anti-tumour therapy; (4)
XX      identifying an agent (A) having anti-cell proliferative activity; and (5)
XX      a kit comprising the agent, and instructions for administering the agent
XX      to a subject in need of treatment on a label or packaging insert. (A) has
XX      cytostatic activity, and can be used in gene therapy. The methods are
XX      useful for treating a cell proliferative disorder, e.g. tumour, such as
XX      sarcoma, melanoma, myeloma, blastoma, glioma, lymphoma or leukaemia. The
XX      present sequence represents a translation enhancer element in the 5'
XX      untranslated region of a human heat shock protein 70 (hsp70) sequence
XX      comprising nucleotides 276 to 488 from the human hsp70 nucleotide
XX      sequence of GenBank accession number M11717, which is used in an example
XX      from the present invention. Human hsp70 is located on chromosome 6, more
XX      specifically 6p21.3.

```


Sequence 213 BP; 40 A; 71 C; 63 G; 39 T; 0 U; 0 Other;
Query Match 99.1%; Score 213; DB 12; Length 213;
Best Local Similarity 100.0%; Pred. No. 2.6e-54;
Matches 213; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 AACGGCTAGCCCTGAGAGAGCTGCTGCGACAGTGCATCACTTTTTCAGAGTGAATCCCGT 62
DB 1 AACGGCTAGCCCTGAGAGAGCTGCTGCGACAGTGCATCACTTTTTCAGAGTGAATCCCGT 60
QY 63 TGTCCCAAGGCTTCCCGAGAGCGAAGCTGCGGCTGACAGACCGGCGGCTGAGTTTC 122
DB 61 TGTCCCAAGGCTTCCCGAGAGCGAAGCTGCGGCTGACAGACCGGCGGCTGAGTTTC 120
QY 123 GCGGCTCCGAGAGAGCGAGCTCTTCTCGGAGATCCAGTGTTCGTTTCAGCCCCCAATC 182
DB 121 GCGGCTCCGAGAGAGCGAGCTCTTCTCGGAGATCCAGTGTTCGTTTCAGCCCCCAATC 180
QY 183 TCAGAGCCGAGCCGACAGAGAGAGGAAACCGC 215
DB 181 TCAGAGCCGAGCCGACAGAGAGAGGAAACCGC 213

RESULT 14
AAA97541
ID AAA97541 standard; cDNA; 2700 BP.
XX
AC AAA97541;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human Hep72 (heat shock protein 72) cDNA.
XX
KW Human Hep72; heat shock protein 72; chromosome 6p21.3; Hep72 inhibitor;
KW expression modulator; JNK phosphatase inhibitor; antiproliferative;
KW drug screening; cancer; leukemia; lymphoma; solid tumor; sarcoma;
KW carcinoma; breast cancer; prostate cancer; premalignant condition; ss.
OS Homo sapiens.
XX
PN WO200054814-A1.
XX
PD 21-SEP-2000.
XX
PF 17-MAR-2000; 2000WO-US007350.
XX
PR 18-MAR-1999; 99US-0125046P.
XX
PA (PHYL-) PHYLOGENY INC.
XX
PI Volloch VZ, Sherman M;
XX
PI MPI; 2000-647056/62.
XX
DR P-PSDB; AAB23252.
XX
PT Identifying compounds that inhibit proliferation of cells and capable of
PT modulating the expression of heat shock protein 72 gene and/or activity
PT of Hep72 useful for treating cancers such as leukemia, lymphoma.
XX
XX Example; Fig 16A; 77pp; English.
XX
XX The invention relates to a novel method of identifying compounds that
XX inhibit proliferation of cells comprising contacting a test compound with
XX a cell which overexpresses Hep72 (heat shock protein 72), and determining
XX if the test compound inhibits activity or expression of Hep72.
XX Optionally, Hep72 is contacted with the test compound under optimum
XX conditions to allow the two components to interact and bind, forming a
XX complex which is detected. The invention also relates to a method of
XX identifying compounds that inhibit Hep72-mediated JNK phosphatase
XX activation, comprising contacting a test compound with a cell which
XX expresses Hep72, exposing the cell to a heat induced stress and
XX determining if the compound inhibits JNK phosphatase activity. The
XX invention additionally encompasses compositions comprising an inhibitor

CC of Hep72 or JNK phosphatase activity. The compounds identified as
CC inhibitors of Hep72 or JNK phosphatase activity are useful for inhibiting
CC the proliferation of cells. Modulation of the activity of the JNK
CC phosphatase or Hep72 is used to treat a proliferative disorder such as
CC cancers (e.g., leukemia, lymphoma, solid tumours such as sarcomas and
CC carcinomas, breast cancer, prostate cancer). The compounds that inhibit
CC Hep72 activity can also be administered to treat premalignant conditions
CC and to prevent progression to a neoplastic or malignant state. The
CC compounds that inhibit Hep72 function are administered to a patient
CC having a disease or disorder mediated by an increase of Hep72 expression
CC or activity relative to normal levels. The present sequence represents
CC cDNA encoding human Hep72 used in the exemplifications of the invention
XX

Sequence 2700 BP; 601 A; 780 C; 834 G; 485 T; 0 U; 0 Other;
Query Match 98.8%; Score 212.4; DB 3; Length 2700;
Best Local Similarity 99.5%; Pred. No. 6.9e-54;
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGCCCTGAGAGAGCTGCTGCGACAGTGCATCACTTTTTCAGAGTGAATCCCG 60
DB 274 ATAAAGGCTAGCCCTGAGAGAGCTGCTGCGACAGTGCATCACTTTTTCAGAGTGAATCCCG 333
QY 61 GTTGTCCCAAGGCTTCCCGAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTCGAGTTT 120
DB 334 GTTGTCCCAAGGCTTCCCGAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTCGAGTTT 393
QY 121 CCGGGGTCGAGAGAGAGCGAGCTCTTCTCGGAGATCCAGTGTTCGTTTCAGCCCCCA 180
DB 394 CCGGGGTCGAGAGAGAGCGAGCTCTTCTCGGAGATCCAGTGTTCGTTTCAGCCCCCA 453
QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 214
DB 454 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 487

RESULT 15
ADM02338
ID ADM02338 standard; cDNA; 1903 BP.
XX
AC ADM02338;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human cDNA of the invention SEQ ID NO:1023.
XX
KW ss; gene; human; gene therapy; diagnostic marker; pharmaceutical.
XX
OS Homo sapiens.
XX
PN EP1347046-A1.
XX
PD 24-SEP-2003.
XX
PF 12-APR-2002; 2002EP-00008400.
XX
PR 22-MAR-2002; 2002JP-00137785.
XX
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
PI Seki N, Yoshikawa T, Otsuka M, Nagahara K, Masuno Y;
XX
DR MPI; 2003-723558/69.
XX
DR P-PSDB; ADM04781.
XX
PT New polynucleotides and polypeptides are useful in gene therapy, for
PT developing a diagnostic marker or medicines for regulating their
PT expression and activity, or as a target of gene therapy.
XX
XX Claim 1; SEQ ID NO 1023; 305pp; English.
XX

CC The invention relates to a novel human polynucleotide and the encoded
CC polypeptide. A polynucleotide of the invention may have a use in gene
CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
CC as a primer for synthesizing the polynucleotide or as a probe for
CC detecting the polynucleotide. The polynucleotides ADM0316-ADM03758 are
CC useful in gene therapy, for developing a diagnostic marker or medicines
CC for regulating their expression and activity, or as a target of gene
CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
CC are useful as pharmaceutical agents. The present sequence represents a
CC cDNA sequence of the invention.

xx
SQ Sequence 1903 BP; 425 A; 531 C; 590 G; 357 T; 0 U; 0 Other;

Query Match 97.9%; Score 210.4; DB 11; Length 1903;

Best Local Similarity 99.5%; Pred. No. 2.6e-53;

Matches 211; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY	3	AACGGCTAGCCTGAGGAGCTGCTGGGACAGTCCACTTCTTTGAGAGTGA	CTCCCGT	62	
DB	1	AACGGCTAGCCTGAGGAGCTGCTGGGACAGTCCACTTCTTTGAGAGTGA	CTCCCGT	60	
QY	63	TGTCCCAAGGCTTCCAGAGCGA	ACTGTGCGGCTGCAGGCA	CCGGCGCTCGAGTTTC	122
DB	61	TGTCCCAAGGCTTCCAGAGCGA	ACTGTGCGGCTGCAGGCA	CCGGCGCTCGAGTTTC	120
QY	123	GCGGTCCGGAAGAGCCGAGCTTCTTCGCGATCCAGTTC	CGTTTCCAGCCCCCAATC	182	
DB	121	GCGGTCCGGAAGAGCCGAGCTTCTTCGCGATCCAGTTC	CGTTTCCAGCCCCCAATC	180	
QY	183	TCAGAGCCGAGCGACAGAGAGAGGAA	CCG	214	
DB	181	TCAGAGCCGAGCGACAGAGAGGAA	CCG	212	

Search completed: February 11, 2005, 08:17:28
Job time : 224 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 11, 2005, 07:52:23 / Search time 87 Seconds
(without alignments)
4043.672 Million cell updates/sec

Title: US-09-936-506-1
Perfect score: 215
Sequence: 1 ataacgctagcctcagcagag.....gacagagacgagcagccgc 215

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 2405568

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents, NA: *
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq: *
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq: *
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq: *
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq: *
5: /cgn2_6/ptodata/1/ina/PTCUS.COMB.seq: *
6: /cgn2_6/ptodata/1/ina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	215	100.0	533	1 US-07-975-719-2	Sequence 2, Appl1
2	215	100.0	533	2 US-08-599-825-2	Sequence 2, Appl1
3	215	100.0	533	3 US-09-048-488-2	Sequence 2, Appl1
4	215	100.0	2691	4 US-08-955-565A-1	Sequence 144, App
5	191.4	89.0	2412	4 US-09-919-039-144	Sequence 827, App
6	187.4	87.2	420	4 US-09-621-976-827	Sequence 145, App
7	156.8	72.9	2458	4 US-09-919-039-145	Sequence 996, App
8	99.2	46.1	1941	4 US-09-976-594-996	Sequence 1, Appl1
9	36.6	17.0	750	1 US-08-599-825-1	Sequence 1, Appl1
10	36.6	17.0	750	2 US-09-048-488-1	Sequence 11809, A
11	36.6	17.0	750	4 US-09-252-991A-11809	Sequence 11869, A
12	33.6	15.6	1074	4 US-09-252-991A-11809	Sequence 6467, Ap
13	33.6	15.6	1120	4 US-09-313-294A-6467	Sequence 4475, Ap
14	32.4	15.1	1205	4 US-09-902-540-4475	Sequence 1221, Ap
15	32.4	15.1	1728	4 US-09-902-540-1221	Sequence 1111, Ap
16	32.4	15.1	28172	4 US-09-902-540-1111	Sequence 14, Appl
17	32.2	15.0	17938	4 US-08-979-608A-14	Sequence 14, Appl
18	31.8	14.8	4722	4 US-09-517-849-14	Sequence 14, Appl
19	31.8	14.8	4722	4 US-09-616-289-14	Sequence 17483, A
20	31.8	14.8	27825	4 US-08-167-939A-5	Sequence 5, Appl1
21	31.6	14.7	1196	1 US-08-567-538-5	Sequence 17939, A
22	31.6	14.7	1196	4 US-09-949-016-1783	Sequence 125345, Sequence 125356, Sequence 11756, A
23	31.6	14.7	1196	1 US-08-567-538-5	
24	31.4	14.6	601	4 US-09-949-016-17939	
25	31.4	14.6	601	4 US-09-949-016-125345	
26	31.4	14.6	601	4 US-09-949-016-125356	
27	31.4	14.6	11752	4 US-09-949-016-11756	

28	31.4	14.6	11865	4 US-09-949-016-15297	Sequence 15297, A
29	31.4	14.6	11865	4 US-09-949-016-15298	Sequence 15298, A
30	30.8	14.3	1638	4 US-09-902-540-2856	Sequence 2856, Ap
31	30.8	14.3	15132	4 US-09-902-540-1137	Sequence 1137, Ap
32	30.4	14.1	603	4 US-09-902-540-9070	Sequence 9070, Ap
33	30.4	14.1	834	4 US-09-621-976-2574	Sequence 969, App
34	30.4	14.1	7719	4 US-09-408-020-3	Sequence 3, Appl1
35	30	14.0	10419	4 US-09-949-016-11412	Sequence 13142, A
36	30	14.0	19157	4 US-09-408-020-2	Sequence 2, Appl1
37	30	14.0	42432	4 US-09-949-016-30895	Sequence 30895, A
38	29.6	13.8	601	4 US-09-949-016-30896	Sequence 30896, A
39	29.6	13.8	601	4 US-09-949-016-105265	Sequence 105265, Sequence 105266, Sequence 12409, A
40	29.6	13.8	601	4 US-09-949-016-105266	Sequence 14680, A
41	29.6	13.8	601	4 US-09-949-016-12409	Sequence 13118, A
42	29.6	13.8	16572	4 US-09-949-016-14680	Sequence 11809, A
43	29.6	13.8	16578	4 US-09-949-016-14680	
44	29.6	13.8	107800	4 US-09-949-016-11118	
45	29.6	13.8	116425	4 US-09-949-016-11809	

ALIGNMENTS

RESULT 1
US-07-975-719-2
; Sequence 2, Application US/07975719
; Patent No. 5521084
; GENERAL INFORMATION:
; APPLICANT: KOMALSKI, JACEK
; APPLICANT: GILBERT, SCOTT
; APPLICANT: ZAMB, TIMOTHY J.
; TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
; TITLE OF INVENTION: THEREOF
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROBERTA L. ROBINS
; STREET: 635 BRYANT STREET
; CITY: PALO ALTO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/975, 719
; FILING DATE: 19921113
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: ROBINS, ROBERTA L.
; REGISTRATION NUMBER: 33, 208
; REFERENCE/DOCKET NUMBER: 9001-0003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 617-8999
; TELEFAX: (415) 327-3231
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 533 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-07-975-719-2
Query Match 100.0%; Score 215; DB 1; Length 533;
Best local Similarity 100.0%; Pred. No. 5.6e-57;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ATAAAGGCTAGCCTGAGAGCTGTCGACAGCTCACTTCTTTTCGAGAGTACTCCC 60
Db 225 ATAAAGGCTAGCCTGAGAGCTGTCGACAGCTCACTTCTTTTCGAGAGTACTCCC 294

Qy	Db	Qy	Db	Qy	Db
61	295	121	355	181	415
GTGTGTC	GTGTGTC	CCGGGCT	CCGGGCT	TCTCAGAG	TCTCAGAG
CCAAAGCTT	CCAAAGCTT	CCGAAAGCA	CCGAAAGCA	CCGACCA	CCGACCA
CCAGAGGAA	CCAGAGGAA	CCGAGCTT	CCGAGCTT	CCAGAGCA	CCAGAGCA
CTGTGGGCT	CTGTGGGCT	CTCTGGCGA	CTCTGGCGA	CCAGAGCA	CCAGAGCA
GTGACGAGA	GTGACGAGA	TCGATGTT	TCGATGTT	CCAGAGCA	CCAGAGCA
CCGGCGCGT	CCGGCGCGT	CGTTCCGTT	CGTTCCGTT	CCAGAGCA	CCAGAGCA
CGAGATT	CGAGATT			CCAGAGCA	CCAGAGCA
120	354	180	414		

RESULT 2
US-08-599-825-2

```

1 Sequence 2, Application US/08599825
2 Patent No. 5733745
3
4 GENERAL INFORMATION:
5
6 APPLICANT: KOMALSKI, JACEK
7 APPLICANT: GILBERT, SCOTT
8 APPLICANT: ZAMB, TIMOTHY J.
9 TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
10 TITLE OF INVENTION: THEREOF
11 NUMBER OF SEQUENCES: 2
12
13 CORRESPONDENCE ADDRESS:
14 ADDRESSEE: ROBERTA L. ROBINS
15 STREET: 285 HAMILTON AVENUE, SUITE 200
16
17 CITY: PALO ALTO
18 STATE: CALIFORNIA
19 COUNTRY: UNITED STATES OF AMERICA
20 ZIP: 94301
21
22 COMPUTER READABLE FORM:
23 MEDIUM TYPE: Floppy disk
24 COMPUTER: IBM PC compatible
25 OPERATING SYSTEM: PC-DOS/MS-DOS
26 SOFTWARE: PatentIn Release #1.0, Version #1.25
27
28 CURRENT APPLICATION DATA:
29 APPLICATION NUMBER: US/08/599,825
30
31 FILING DATE:
32
33 CLASSIFICATION: 435
34
35 ATTORNEY/AGENT INFORMATION:
36 NAME: ROBINS, ROBERTA L.
37 REGISTRATION NUMBER: 33,208
38 REFERENCE/DOCKET NUMBER: 9001-0003.01
39
40 TELECOMMUNICATION INFORMATION:
41 TELEPHONE: (415) 327-3400
42 TELEFAX: (415) 327-3321
43
44 INFORMATION FOR SEQ ID NO: 2:
45
46 SEQUENCE CHARACTERISTICS:
47 LENGTH: 533 base pairs
48 TYPE: nucleic acid
49 STRANDEDNESS: single
50
51 TOPOLOGY: linear
52
53 MOLECULE TYPE: DNA (genomic)
54
55 US-08-599-825-2

```

Query Match	100.0%;	Score 215;	DB 1;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 5.6e-57;		
Matches 215; Conservative	0;	Mismatches	0;	Gaps 0

Qy 181 TCTCAGAGCCGAGGCCACAGAGACGAGGAACCGC 215
| | | | |
Db 415 TCTCAGAGCCGAGGCCACAGAGACGAGGAACCGC 449

RESULT 3
US-09-048-488-2

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

Query Match	100.0%;	Score 215;	DB 2;	Length 533;
Best Local Similarity	100.0%;	Pred. No. 5.6e-57;		
Matches 215;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

[illegible]

RESULT 4

US-08-955-565A-1
; Sequence 1, Application US/08955565A
; Patent No. 631388
; GENERAL INFORMATION:
; APPLICANT: Malkovsky, Miroslav
; APPLICANT: Wells, Andrew
; TITLE OF INVENTION: Immune Response Enhancer Therapy
; FILE REFERENCE: MARF-02625
; CURRENT APPLICATION NUMBER: US/08/955,565A
; CURRENT FILING DATE: 1997-10-17
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patent version 3.0
; SEQ ID NO 1
; LENGTH: 2691
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-955-565A-1

Query Match 100.0%; Score 215; DB 3; Length 2691;
Best Local Similarity 100.0%; Pred. No. 8.7e-57;
Matches 215; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTCTTTTTCAGAGTGAAGTCCC 60
DB 274 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTCTTTTTCAGAGTGAAGTCCC 333
QY 61 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
DB 334 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 393
QY 121 CCGGGCTCCGAGGACCGAGCTCTTCTGCGGATCAGTGTTCGTTTCCAGCCCCCA 180
DB 394 CCGGGCTCCGAGGACCGAGCTCTTCTGCGGATCAGTGTTCGTTTCCAGCCCCCA 453
QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCCG 215
DB 454 TCTCAGAGCCGAGCCGAGAGAGAGGAAACCCG 488

RESULT 5

US-09-919-039-144
; Sequence 144, Application US/09919039
; Patent No. 6727066
; GENERAL INFORMATION:
; APPLICANT: Kaser, Matthew R.
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/09/919,039
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 60/222,113
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PERL Program
; SEQ ID NO 144
; LENGTH: 2412
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. 6727066 242010.16
US-09-919-039-144

Query Match 89.0%; Score 191.4; DB 4; Length 2412;
Best Local Similarity 99.0%; Pred. No. 1.7e-49;
Matches 203; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 11 GCGTGAAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAAGTCCCGTTGCCAA 70
DB 1 GCGTGAAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAAGTCCCGTTGCCAA 60
QY 71 GCGTCCCAAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTCC 129
DB 61 GCGTCCCAAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTCC 120

QY 120 GGAAGACCGAGCTCTTCTCGCGATCCAGTGTTCGTTTCCAGCCCCCAATCTGAGAC 189
DB 121 GGAAGACCGAGCTCTTCTCGCGATCCAGTGTTCGTTTCCAGCCCCCAATCTGAGAC 180
QY 190 CGAGCCGACAGAGAGCGAAGCCG 214
DB 181 CGAGCCGACAGAGAGCGAAGCCG 205

RESULT 6

US-09-621-976-827
; Sequence 827, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
; APPLICANT: Dumae Milne Edwards, J.B.
; APPLICANT: Jodert, S.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: ESTs and Encoded Human Proteins.
; FILE REFERENCE: GENSET.054PR2
; CURRENT APPLICATION NUMBER: US/09/621,976
; CURRENT FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 19335
; SOFTWARE: Patent.pm
; SEQ ID NO 827
; LENGTH: 420
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 218..418
US-09-621-976-827

Query Match 87.2%; Score 187.4; DB 4; Length 420;
Best Local Similarity 97.7%; Pred. No. 1.8e-48;
Matches 210; Conservative 1; Mismatches 2; Indels 2; Gaps 2;

QY 1 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTCTTTTTCAGAGTGAAGTCCC 60
DB 2 ATAAAGGCTAGGCTTGAAGAGCTGCTCCGACAGTCCACTCTTTTTCAGAGTGAAGTCCC 61
QY 61 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
DB 62 GTTGTCCCAAGGCTTCCGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 121
QY 121 CCGGGCTCCGAGGACCGAGCTCTTCTGCGGATCAGTGTTCGTTTCCAGCCCCCA 179
DB 122 CCGGGCTCCGAGGACCGAGCTCTTCTGCGGATCAGTGTTCGTTTCCAGCCCCCA 181
QY 180 ATCTCAGAGCCGAGCCGACAGAGAGAGGAAACCCG 214
DB 182 ATCTCAGAGCCGAGCCGACAGAGAGGAAACCCG 215

RESULT 7

US-09-919-039-145
; Sequence 145, Application US/09919039
; Patent No. 6727066
; GENERAL INFORMATION:
; APPLICANT: Kaser, Matthew R.
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/09/919,039
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 60/222,113
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PERL Program
; SEQ ID NO 145
; LENGTH: 2458
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:

QY 11 GCGTGAAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAAGTCCCGTTGCCAA 70
DB 1 GCGTGAAGAGCTGCTGCGACAGTCCACTCTTTTTCAGAGTGAAGTCCCGTTGCCAA 60
QY 71 GCGTCCCAAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTCC 129
DB 61 GCGTCCCAAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTTCCGCGCTCC 120

```
/ NAME/KEY: misc feature
/ OTHER INFORMATION: Incyte ID No. 6727066 1678695CBI
US-09-919-039-145

Query Match      72.9%; Score 156.8; DB 4; Length 2458;
Best Local Similarity 88.5%; Pred. No. 8.6e-39;
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 11 GCGTGAAGAGCTGCTGCGAGCAGTCCACTACCTTTTTCGAGAGTACTCCCGTTGTCCTCA 70
DB 1 GCGTGAAGAGCTGCTGCGAGGCTCCGCTTCGTTTCGAGAGTACTCCCGGCTCCAA 60
QY 71 GCGTTCCCGAGCGAACTGTGCGGCTGAGGACCGCGCGCTCGAGTTTCCGGCGTCCG 130
DB 61 GCGTTCCCGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGTGAGTTTCCGGCGTCC 120
QY 131 GAAGACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCAATCTCAGAGCC 190
DB 121 GAAGACCTAGCTCTTGTGCGGATCCGTCGCGCTTCGCGCCCACTCAGAGCG 180
QY 191 GAGCCGACAGAG 202
DB 181 GAGCCGACAGAG 192

RESULT 8
US-09-976-594-996
/ Sequence 996, Application US/09976594
/ Patent No. 6673549
/ GENERAL INFORMATION:
/ APPLICANT: Furness, Michael
/ APPLICANT: Buchdinder, Jenny
/ TITLE OF INVENTION: GENES EXPRESSED IN C3A LIVER CELL CULTURES TREATED WITH STEROIDS
/ FILE REFERENCE: PA-0041 US
/ CURRENT APPLICATION NUMBER: US/09/976,594
/ PRIOR FILING DATE: 2001-10-12
/ PRIOR APPLICATION NUMBER: 60/240,409
/ NUMBER OF SEQ ID NOS: 1143
/ SOFTWARE: PERL Program
/ SEQ ID NO 996
/ LENGTH: 1941
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ NAME/KEY: misc feature
/ OTHER INFORMATION: Incyte ID No. 6673549 242010.60
US-09-976-594-996

Query Match      46.1%; Score 99.2; DB 4; Length 1941;
Best Local Similarity 89.2%; Pred. No. 5.3e-21;
Matches 107; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 89 CGAAGCTGGCGGCTGCGAGCAGCCGCGGCTGAGTTTCCGCGCTCCGGAAGACCGAGC 142
DB 1 CGAAGCTGGCGGCTGCGAGCAGCCGCGGCTGAGTTTCCGCGCTCCGGAAGACTGAGC 60
QY 143 TCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCAATCTCAGAGCCGAGCGAGAG 202
DB 61 TCTTCTCGCGGATCCGCTCGCGGCTTCCAGCCCCCAATCTCAGAGCCGAGCGAGAG 120

RESULT 9
US-07-975-719-1
/ Sequence 1, Application US/07975719
/ Patent No. 5521084
/ GENERAL INFORMATION:
/ APPLICANT: KOMALSKI, JACEK
/ APPLICANT: GILBERT, SCOTT
/ APPLICANT: ZAMB, TIMOTHY J.
/ TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
/ TITLE OF INVENTION: THEREOF
/ NUMBER OF SEQUENCES: 2
```

```
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ROBERTA L. ROBINS
/ STREET: 635 BRYANT STREET
/ CITY: PALO ALTO
/ STATE: CALIFORNIA
/ COUNTRY: UNITED STATES OF AMERICA
/ ZIP: 94301
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ FILING DATE: 19921113
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: ROBINS, ROBERTA L.
/ REGISTRATION NUMBER: 33,208
/ REFERENCE/DOCKET NUMBER: 9001-0003
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 617-8999
/ TELEFAX: (415) 327-3231
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 750 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-07-975-719-1

Query Match      17.0%; Score 36.6; DB 1; Length 750;
Best Local Similarity 66.0%; Pred. No. 0.096;
Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;

QY 101 GGCACCGCGCGCTCAGTTCGCGGCTCCGGAAGACCGAGC-TTCTTCGCGGATCCAG 159
DB 552 GGCACCAAGAGCGTTAGTTTCGCGGCTCCGAAMACCGAGGCTTCGTCGAGATCTTC 611
QY 160 TGTTCCGTTTCAGCGCCCAATCTCAGAGCGGCGGAGAG 202
DB 612 TTCACCGATTTGAGGTTTGAGAGCTTATTTCCGAGCGGAGAAAG 654

RESULT 10
US-08-599-825-1
/ Sequence 1, Application US/08599825
/ Patent No. 5733745
/ GENERAL INFORMATION:
/ APPLICANT: KOMALSKI, JACEK
/ APPLICANT: GILBERT, SCOTT
/ APPLICANT: ZAMB, TIMOTHY J.
/ TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
/ TITLE OF INVENTION: THEREOF
/ NUMBER OF SEQUENCES: 2
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ROBERTA L. ROBINS
/ STREET: 285 HAMILTON AVENUE, SUITE 200
/ CITY: PALO ALTO
/ STATE: CALIFORNIA
/ COUNTRY: UNITED STATES OF AMERICA
/ ZIP: 94301
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ FILING DATE:
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
```

NAME: ROBINS, ROBERTA L.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 9001-0003.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 327-3400
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 750 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-599-825-1

Query Match
Best Local Similarity 17.0%; Score 36.6; DB 1; Length 750;
Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;

QY 101 GGCACCGCGCGCTCAGTTTCCGGCGTCCGGAAGACCGAGC-TCTTCTCGCGATCCAG 159
DB 552 GGCACCGAGCGCTTACGTTTTCGGGTCCGAAAGCCGAGCTTCTCGTCCGAGATCTTC 611

QY 160 TGTTCGTTTCCAGCCCCCAATCTCAGAGCCGAGCCGACAGG 202
DB 612 TTCACCGATTTCAGGTTTGAACTTATTTCGAGCCGGAAG 654

RESULT 11
US-09-048-488-1
Sequence 1, Application US/09048488
Patent No. 5981224
GENERAL INFORMATION:
APPLICANT: KOMALSKI, JACEK
APPLICANT: GILBERT, SCOTT
APPLICANT: ZAMB, TIMOTHY J.
TITLE OF INVENTION: BOVINE HEAT SHOCK PROMOTER AND USES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSER: ROBERTA L. ROBINS
STREET: 635 BRYANT STREET
CITY: PALO ALTO
STATE: CALIFORNIA
COUNTRY: UNITED STATES OF AMERICA
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/048,488
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/975,719
FILING DATE: 1992-11-13
ATTORNEY/AGENT INFORMATION:
NAME: ROBINS, ROBERTA L.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 9001-0003
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 617-8999
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 750 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-048-488-1

Query Match
Best Local Similarity 17.0%; Score 36.6; DB 2; Length 750;
Matches 68; Conservative 0; Mismatches 34; Indels 1; Gaps 1;

QY 101 GGCACCGCGCGCTCAGTTTCCGGCGTCCGGAAGACCGAGC-TCTTCTCGCGATCCAG 159
DB 552 GGCACCGAGCGCTTACGTTTTCGGGTCCGAAAGCCGAGCTTCTCGTCCGAGATCTTC 611

QY 160 TGTTCGTTTCCAGCCCCCAATCTCAGAGCCGAGCCGACAGG 202
DB 612 TTCACCGATTTCAGGTTTGAACTTATTTCGAGCCGGAAG 654

RESULT 12
US-09-252-991A-11809/c
Sequence 11809, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
PRIOR FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 11809
LENGTH: 1074
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-11809

Query Match
Best Local Similarity 15.6%; Score 33.6; DB 4; Length 1074;
Matches 57; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 82 GCGAAGCTGTGGGCTGCAAGCGGCGGCGCTTCGAGTTTCCGGCTCCGAAAGACCGAG 141
DB 828 GCGATCCTGTGGGCTGCAAGCGGCGGCGCTTCGAGTTTCCGGCTCCGAAAGACCGAG 769

QY 142 CTCTTCGCGGATCCAGGTTCGTTCCAGCCCC 177
DB 768 GAGATCGCGCAGTCTAGGCTTCCAGCCCGAGCCCC 733

RESULT 13
US-09-252-991A-11869/c
Sequence 11869, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
PRIOR FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 11869
LENGTH: 1320
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-11869

Query Match
Best Local Similarity 15.6%; Score 33.6; DB 4; Length 1320;
Matches 59.4%; Pred. No. 0.95;

Matches 57; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 82 GCGAAGCTGTGGCTGTGAGGACCGCGCGTGTGAGTTTCCGCGTCCGGAAGACCGAG 141
DB 1103 GCGATCTGTGTGGTGTGAGCGCCATCGGCGTGTGAGTTTCCGCGTCCGGAAGACCGAG 1044
QY 142 CTCCTTCTGCGGATCCAGTGTTCGTTTCCAGCCCC 177
DB 1043 GAGATCGGCGAGTCTGTAGGCTTCCAGCCAGGCC 1008

RESULT 14
US-09-313-294A-6467
; Sequence 6467, Application US/09313294A
; Patent No. 6476212
; GENERAL INFORMATION:
; APPLICANT: Lalgudi, Raghunath V.
; APPLICANT: Ito, Laura Y.
; APPLICANT: Sherman, Bradley K.
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN EAR
; FILE REFERENCE: PL-0017 US
; CURRENT APPLICATION NUMBER: US/09/313,294A
; CURRENT FILING DATE: 1999-05-14
; NUMBER OF SEQ ID NOS: 7600
; SOFTWARE: PERL Program
; SEQ ID NO 6467
; LENGTH: 205
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No. 6476212 700351854H1
; NAME/KEY: unsure
; LOCATION: 31, 178, 202-203
; OTHER INFORMATION: a, t, c, g, or other
US-09-313-294A-6467

Query Match 15.1%; Score 32.4; DB 4; Length 205;
Best Local Similarity 68.2%; Pred. No. 1.3;
Matches 45; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 149 CCGGATCCAGTGTTCGTTTCCAGCCCCCAATCTCAGAGCCGCGGACGAGAGACGAG 208
DB 80 CACGAGCAAGAGATTCTGTCTGCAATTATTAACGAGCCGAGAGAGGTCAAG 139
QY 209 GAACCG 214
DB 140 CAACCG 145

RESULT 15
US-09-902-540-4475/C
; Sequence 4475, Application US/09902540
; Patent No. 6833447
; GENERAL INFORMATION:
; APPLICANT: Goldman, Barry S.
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Wiegand, Roger C.
; TITLE OF INVENTION: Myxococcus xanthus Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15849)B
; CURRENT APPLICATION NUMBER: US/09/902,540
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: 60/217,883
; PRIOR FILING DATE: 2000-07-10
; NUMBER OF SEQ ID NOS: 16825
; SEQ ID NO 4475
; LENGTH: 1728
; TYPE: DNA
; ORGANISM: Myxococcus xanthus
US-09-902-540-4475

Query Match 15.1%; Score 32.4; DB 4; Length 1728;

Best Local Similarity 50.0%; Pred. No. 2.4;
Matches 81; Conservative 0; Mismatches 81; Indels 0; Gaps 0;
QY 16 AGAAGCTGTGAGACAGTCCACTACTTTTGAAGAGTGTCCGTTGTCCAAAGCTT 75
DB 1628 AGAAGTGTGTGCGCCAGCGGTCCAGCTCTTGTGAGCTTGAATCCGTGAGCAGCGCGCTC 1569
QY 76 CCGAGAGCAACTGTGTGGCTGTGAGGACCGGCGGTGTGAGTTTCCGCGTCCGAAGG 135
DB 1568 GCCTGCCGCGCGGTGTCCGCAAGCGCGTCTCACCCATGAGCGGTGATGCGGTCAAG 1509
QY 136 ACCGAGCTTCTGTGCGGATCCAGTGTTCGTTTCCAGCCCC 177
DB 1508 GCCAGTGAATTTCCGGTTCGAACGGGTCCAGCGCCAGCGCC 1467

Search completed: February 11, 2005, 09:04:16
Job time : 89 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using SW model

Run on: February 11, 2005, 08:35:16 ; Search time 259 Seconds

(without alignments)
4898.065 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215
1 ataacgcctagcctcgagag.....gacagagcagcggaaccgc 215

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 5378673 seqs, 2950229984 residues

Total number of hits satisfying chosen parameters: 10757346

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications NA: *
1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq: *
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq: *
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq: *
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq: *
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq: *
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq: *
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq: *
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq: *
9: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq: *
10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq: *
11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq: *
12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq: *
13: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq: *
14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq: *
15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq: *
16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq: *
17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq: *
18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq: *
19: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq: *
20: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq: *
21: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq: *
22: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	214	99.5	2732	US-10-335-053-291	Sequence 291, App
2	213.4	99.3	549	US-10-348-359-1	Sequence 1, Appl
3	210.4	97.9	1903	US-10-108-260A-1023	Sequence 1023, Ap
4	195	90.7	2287	US-10-172-118-1144	Sequence 1144, Ap
5	195	90.7	2287	US-10-342-887-1144	Sequence 1144, Ap
6	191.4	89.0	2412	US-09-919-039-144	Sequence 144, App
7	163.6	76.1	504	US-10-028-386-6557	Sequence 6557, Ap
8	158.2	73.6	286	US-10-425-115-89981	Sequence 8981, A
9	156.8	72.9	2458	US-09-918-039-145	Sequence 145, App
10	156.8	72.9	2513	US-10-335-053-290	Sequence 290, App
11	156.4	72.7	2771	US-10-027-632-111980	Sequence 111980,

C 12	156.4	72.7	2771	17	US-10-027-632-111980	Sequence 111980,
C 13	145.2	67.5	595	18	US-10-363-345A-17429	Sequence 17429, A
C 14	145.2	67.5	595	18	US-10-363-345A-17430	Sequence 17430, A
C 15	145.2	67.5	596	18	US-10-363-345A-20731	Sequence 20731, A
C 16	145.2	67.5	596	18	US-10-363-345A-20732	Sequence 20732, A
C 17	145.2	67.5	9899	15	US-10-311-455-2415	Sequence 2415, Ap
C 18	145.2	67.5	3673778	16	US-10-312-841-1	Sequence 2, Appl
C 19	134	62.3	595	18	US-10-363-345A-17431	Sequence 17431, A
C 20	134	62.3	595	18	US-10-363-345A-17432	Sequence 17432, A
C 21	134	62.3	596	18	US-10-363-345A-20729	Sequence 20729, A
C 22	134	62.3	9899	15	US-10-363-345A-20730	Sequence 20730, A
C 23	134	62.3	9899	15	US-10-311-455-2416	Sequence 2416, Ap
C 24	134	62.3	3673778	16	US-10-312-841-1	Sequence 1, Appl
C 25	116.6	54.2	2460	18	US-10-370-715B-21	Sequence 21, Appl
C 26	103.4	48.1	583	18	US-10-363-345A-17425	Sequence 17425, A
C 27	103.4	48.1	583	18	US-10-363-345A-17426	Sequence 17426, A
C 28	99.6	46.3	583	18	US-10-363-345A-17427	Sequence 17427, A
C 29	99.6	46.3	583	18	US-10-363-345A-17428	Sequence 17428, A
C 30	89.2	41.5	584	18	US-10-363-345A-20735	Sequence 20735, A
C 31	89.2	41.5	584	18	US-10-363-345A-20736	Sequence 20736, A
C 32	83.8	39.0	584	18	US-10-363-345A-20733	Sequence 20733, A
C 33	83.8	39.0	584	18	US-10-363-345A-20734	Sequence 20734, A
C 34	58	27.0	939	16	US-10-029-386-20724	Sequence 20724, A
C 35	38.4	17.9	2636	13	US-10-002-600-95	Sequence 95, Appl
C 36	34.2	15.9	2940917	17	US-10-027-632-174763	Sequence 174763,
C 37	34.2	15.9	2940917	17	US-10-027-632-174763	Sequence 174763,
C 38	32.8	15.3	1473	17	US-10-282-122A-14406	Sequence 14406, A
C 39	32.4	15.1	2261	17	US-10-379-381-1	Sequence 273, App
C 40	32.2	15.0	7789	17	US-10-333-314-38	Sequence 38, Appl
C 41	32.2	15.0	9698	17	US-10-210-130-37	Sequence 37, Appl
C 42	32.2	15.0	9807	17	US-10-379-381-1	Sequence 1, Appl
C 43	32.2	15.0	9930	17	US-10-210-130-33	Sequence 33, Appl
C 44	32.2	15.0	10122	17	US-10-210-130-35	Sequence 35, Appl
C 45	32.2	15.0	62805	17	US-10-379-381-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-10-335-053-291
; Sequence 291, Application US/10335053
; Publication No. US20040241653A1
; GENERAL INFORMATION:
; APPLICANT: Quark Biotech, Inc.
; TITLE OF INVENTION: Methods for identifying marker genes for cancer
; FILE REFERENCE: 68733-A, 070/US1
; CURRENT APPLICATION NUMBER: US/10/335,053
; PRIOR FILING DATE: 2003-03-27
; PRIOR APPLICATION NUMBER: 60/345,317
; PRIOR FILING DATE: 2001-12-31
; NUMBER OF SEQ ID NOS: 319
; SOFTWARE: Patencin version 3.2
; SEQ ID NO 291
; LENGTH: 2732
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-335-053-291

Query Match	99.5%	Score 214;	DB 18;	Length 2732;
Best Local Similarity	100.0%	Pred. No. 2.4e-60;		
Matches 214;	Conservative	0;	Mismatches 0;	Indels 0;
			Gaps	0;
QY	1	ATAAGGCTAGGCTGAGAGGCTGCGGACAGTCCACATCTTTTCCAGAGTACCTCC	60	
DB	274	ATAAGGCTAGGCTGAGAGGCTGCGGACAGTCCACATCTTTTCCAGAGTACCTCC	333	
QY	61	GTTGTCCTAGGCTTCCAGAGGCTGCGGCTGAGGACACCGGCGCTCAGATT	120	
DB	334	GTTGTCCTAGGCTTCCAGAGGCTGCGGCTGAGGACACCGGCGCTCAGATT	393	
QY	121	CCGAGGCTCGGAGAGGACGAGCTCTTCTCGGAGATCAAGTGTTCGTTTCCAGCCCA	180	

Db 394 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCAGTGTTCGGTTCCAGCCCCAA 453

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 214

Db 454 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 487

RESULT 2

US-10-348-359-1.
; Sequence 1, Application US/10348359
; Publication No. US20040018178A1
; GENERAL INFORMATION:
; APPLICANT: WEST, MICHAEL
; TITLE OF INVENTION: STEM CELL-DERIVED ENDOTHELIAL CELLS MODIFIED TO DISRUPT
; FILE REFERENCE: 100375, 54374US
; CURRENT APPLICATION NUMBER: US/10/348,359
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 60/349,345
; PRIOR FILING DATE: 2002-01-22
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 1
; LENGTH: 549
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-348-359-1

Query Match 99.3%; Score 213.4; DB 17; Length 549;
Best Local Similarity 99.5%; Pred. No. 3,4e-60;
Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 ATAAAGGCTAGGCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTGACTCCC 60

Db 269 ATAAAGGCTAGGCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTGACTCCC 328

Qy 61 GTTGTCCTCCAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTCGAGTTT 120

Db 329 GTTGTCCTCCAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTCGAGTTT 388

Qy 121 CCGGAGTCCGGAAGAGACCGAGCTCTTCTGCGGATTCAGTGTTCGAGCCGCCAA 180

Db 389 CCGGAGTCCGGAAGAGACCGAGCTCTTCTGCGGATTCAGTGTTCGAGCCGCCAA 448

Qy 181 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCGC 215

Db 449 TCTCAGAGCCGAGCCGACAGAGAGCAGGGAACCGC 483

RESULT 3

US-10-108-260A-1023
; Sequence 1023, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20040005560A1e1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 1023
; LENGTH: 1903
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-108-260A-1023

Query Match 97.9%; Score 210.4; DB 17; Length 1903;
Best Local Similarity 99.5%; Pred. No. 3,6e-59;
Matches 211; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 AACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTGACTCCGT 62

Db 1 AACGGCTAGCCTGAGAGCTGCTGCGACAGTCCACTTCTTTTCGAGAGTGACTCCGT 60

Qy 63 TGTCCAAAGCTTCCAGAGCGAACTGTGCGCTGACGAGACCGCGCGTTCGAGTTTC 122

Db 61 TGTCCAAAGCTTCCAGAGCGAACTGTGCGCTGACGAGACCGCGCGTTCGAGTTTC 120

Qy 123 GCGTCCGGAAGAGACCGAGCTTCTCCGCGATCCAGTGTTCGTTTCCAGCCCCCAATC 182

Db 121 GCGTCCGGAAGAGACCGAGCTTCTCCGCGATCCAGTGTTCGTTTCCAGCCCCCAATC 180

Qy 183 TCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 214

Db 181 TCAGAGCCGAGCCGACAGAGAGCAGGGAACCG 212

RESULT 4

US-10-172-118-1144
; Sequence 1144, Application US/10172118
; Publication No. US20030224374A1
; GENERAL INFORMATION:
; APPLICANT: Dai, Hongyue
; APPLICANT: Dai, Hongyue
; APPLICANT: He, Yundong
; APPLICANT: Linsley, Peter
; APPLICANT: Mao, Mao
; APPLICANT: Roberts, Chris
; APPLICANT: Van 't Veer, Laura
; APPLICANT: Van de Vijver, Marc
; APPLICANT: Bernards, Rene
; TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients
; FILE REFERENCE: 9301-175-999
; CURRENT APPLICATION NUMBER: US/10/172,118
; CURRENT FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: 60/380,770
; PRIOR FILING DATE: 2002-05-14
; NUMBER OF SEQ ID NOS: 2699
; SEQ ID NO: 1144
; LENGTH: 2387
; TYPE: DNA
; ORGANISM: Homo sapiens
; PUBLICATION INFORMATION:
; DATABASE ACCESSION NUMBER: NM_005345
; DATABASE ENTRY DATE: 2001-06-18
US-10-172-118-1144

Query Match 90.7%; Score 195; DB 17; Length 2387;
Best Local Similarity 100.0%; Pred. No. 4,2e-54;
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 20 GCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCGTTGTCCCAAGGCTTCCCA 79

Db 1 GCTGCTGCGACAGTCCACTTCTTTTCGAGAGTACTCCGTTGTCCCAAGGCTTCCCA 60

Qy 80 GAGCGAACCCTGTGCGGCTGCGAGCAACCGCGCGTGTGAATTTCCGCGCTCCGGAAGAACCG 139

Db 61 GAGCGAACCCTGTGCGGCTGCGAGCAACCGCGCGTGTGAATTTCCGCGCTCCGGAAGAACCG 120

Qy 140 AGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGGCCCCCAATTCAGAGCCGAGCCGACA 199

Db 121 AGCTCTTCTCGCGAGTCCAGTGTTCGTTTCCAGGCCCCCAATTCAGAGCCGAGCCGACA 180

Qy 200 GAGAGCAGGGAACCG 214

Db 181 GAGAGCAGGGAACCG 195

RESULT 5

US-10-342-887-1144
; Sequence 1144, Application US/10342887
; Publication No. US20040058340A1
; GENERAL INFORMATION:
; APPLICANT: Dai, Hongyue
; APPLICANT: He, Yundong
; APPLICANT: Linsley, Peter S.

APPLICANT: Mao, Mao
APPLICANT: Roberts, Christopher J.
APPLICANT: Van 't Veer, Laura Johanna
APPLICANT: Van de Vijver, Marc J.
APPLICANT: Bernards, Rene
TITLE OF INVENTION: Diagnosis and Prognosis of Breast Cancer Patients
FILE REFERENCE: 9301-188-999
CURRENT APPLICATION NUMBER: US/10/342,887
CURRENT FILING DATE: 2003-01-15
PRIOR APPLICATION NUMBER: 60/298,918
PRIOR FILING DATE: 2001-06-18
PRIOR APPLICATION NUMBER: 60/380,710
PRIOR FILING DATE: 2002-05-14
PRIOR APPLICATION NUMBER: 10/172,118
PRIOR FILING DATE: 2002-06-14
NUMBER OF SEQ ID NOS: 2699
SEQ ID NO 1144
LENGTH: 2387
TYPE: DNA
ORGANISM: Homo sapiens
US-10-342-887-1144

Query Match 90.7%; Score 195; DB 17; Length 2387;
Best Local Similarity 100.0%; Pred. No. 4.2e-54;
Matches 195; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTGCTGGACAGTCCACTACCTTTTTCGAGAGTGAATCCCGTGTCCCAAGCTTCCCA 79
DB 1 GCTGCTGGACAGTCCACTACCTTTTTCGAGAGTGAATCCCGTGTCCCAAGCTTCCCA 60
QY 80 GAGCGAACCTGTGCGGCTGCAGAGCAACCGCGCGTGCAGATTTTCGCGCGTCCGAGAGACCG 139
DB 61 GAGCGAACCTGTGCGGCTGCAGAGCAACCGCGCGTGCAGATTTTCGCGCGTCCGAGAGACCG 120
QY 140 AGCTTTCTTCGCGGATCCAGATGTTCCGTTTCCAGCCCCCAATCTCAGAGCCGACCGGACA 199
DB 121 AGCTTTCTTCGCGGATCCAGATGTTCCGTTTCCAGCCCCCAATCTCAGAGCCGACCGGACA 180
QY 200 GAGAGCAGGAGAACCG 214
DB 181 GAGAGCAGGAGAACCG 195

RESULT 6
US-09-919-039-144
Sequence 144, Application US/09919039
Publication No. US20030108871A1
GENERAL INFORMATION:
APPLICANT: Kaser, Matthew R.
TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LAYER CELL CULTURES
FILE REFERENCE: PA-0035 US
CURRENT APPLICATION NUMBER: US/09/919,039
CURRENT FILING DATE: 2002-09-09
PRIOR APPLICATION NUMBER: 60/222,113
PRIOR FILING DATE: 2000-07-28
NUMBER OF SEQ ID NOS: 401
SOFTWARE: PERL Program
SEQ ID NO 144
LENGTH: 2412
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Incyte ID No. US20030108871A1 242010.16
US-09-919-039-144

Query Match 89.0%; Score 191.4; DB 10; Length 2412;
Best Local Similarity 99.0%; Pred. No. 6.4e-53;
Matches 203; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 11 GCTTGAAGAGCTGCTGCGACAGTCCACTACCTTTTTCGAGAGTGAATCCCGTGTCCCA 70
DB 1 GCTTGAAGAGCTGCTGCGACAGTCCACTACCTTTTTCGAGAGTGAATCCCGTGTCCCA 60

QY 71 GGCTTCCAGAGCGAAGCTGT-GCGGCTGCAGAGCAACCGCGCGTGCAGATTTTCGCGGCTTC 129
DB 61 GGCTTCCAGAGCGAAGCTGTGCGGCTGCAGAGCAACCGCGCGTGCAGATTTTCGCGGCTTC 120
QY 130 GGAAGACCGAGCTTTCTTCGCGGATCCAGATGTTCCGTTTCCAGCCCCCAATCTCAGAGC 189
DB 121 GGAAGACCGAGCTTTCTTCGCGGATCCAGATGTTCCGTTTCCAGCCCCCAATCTCAGAGC 180
QY 190 CGAGCGGACAGAGCAGGAGAACCG 214
DB 181 GAGCGGACAGAGCAGGAGAACCG 205

RESULT 7
US-10-029-386-6557/c
Sequence 6557, Application US/10029386
Publication No. US20030194704A1
GENERAL INFORMATION:
APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.
APPLICANT: Hanzel, David K.
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
FILE REFERENCE: AEWICA-X-2
CURRENT APPLICATION NUMBER: US/10/029,386
CURRENT FILING DATE: 2001-12-20
NUMBER OF SEQ ID NOS: 34288
SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
SEQ ID NO 6557
LENGTH: 506
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO APL34726.1
OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 5.5
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 4.8
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 3.1
OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 11
OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 7.9
OTHER INFORMATION: SWISSPROT HIT: P08107, EVALUE 2.00e-17
OTHER INFORMATION: NT HIT: M59830.1, EVALUE 0.00e+00
OTHER INFORMATION: EST_HUMAN HIT: BG773197.1, EVALUE 0.00e+00
US-10-029-386-6557

Query Match 76.1%; Score 163.6; DB 16; Length 506;
Best Local Similarity 88.1%; Pred. No. 7.9e-44;
Matches 178; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 1 ATAACGGCTAGCGTAGAGAGCTGCGGACAGTCCACTACCTTTTTCGAGAGTGAATCC 60
DB 339 AAAACGGCGAGCTTAGAGAGCTGCTGCAGAGGTCGCTTCGTTCTTTCAGAGTGAATCC 280
QY 61 GTTGTCCAGAGCTTCCAGAGCAAGCTGTGCGGCTGCAGAGCAACCGCGCGTGCAGATT 120
DB 279 GCGGTCCAGAGCTTTCAGAGCAAGCTGTGCGGCTGCAGAGCAACCGCGGTGTGAGTTT 220
QY 121 CCGGCGTCCGAGAGCAAGAGTCTTTCGCGGATCCAGATGTTCCGTTTCCAGCCCCCA 180
DB 219 CCGGCGTTCGAGAGCAAGAGTCTTTCGCGGATCCAGATGTTCCGTTTCCAGCCCCCA 160
QY 181 TCTCAGAGCGGAGCGAGAGAG 202
DB 159 TCTCAGAGCGGAGCGAGAGAG 138

RESULT 8
US-10-425-115-89981
Sequence 89981, Application US/10425115
Publication No. US20040214272A1
GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.

```

; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO: 89981
; LENGTH: 284
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_182065C.1
; US-10-425-115-89981

Query Match          73.6%; Score 158.2; DB 18; Length 284;
Best Local Similarity 95.3%; Pred. No. 4,5e-42;
Matches 163; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 45 TTCGAGAGTGAAGTCCCGTTTCCCAAGGCTTCCAGAGGAACTGTGGGCTGAGAGCA 104
Db 1 TTCGAGAGTGAAGTCCCGTTTCCCAAGGCTTCCAGAGGAACTGTGGGCTGAGAGCA 60

Qy 105 CCGGCGCGTCCGAGTTTCCGCGGCTCCGGAAGAACCCGAGCTTCTTCCGCGATCCAGTTTC 164
Db 61 CCGGCGCGTCCGAGTTTCCGCGGCTCCGGAAGAACCCGAGCTTCTTCCGCGATCCAGTTTC 120

Qy 165 GCTTCCAGACCCCAATCTCAGAGCCGAGCCGACAGAGAGAGGAGGAGCCGC 215
Db 121 GCTTCCAGACCCCAATCTCAGAGCCGAGCCGAGCCGACAGAGATGCGAGATCCGCGC 171

RESULT 9
US-09-919-039-145
; Sequence 145, Application US/09919039
; Publication No. US20030108871A1
; GENERAL INFORMATION:
; APPLICANT: Kaseg, Matthew R.
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/09/919,039
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 60/222,113
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PERL Program
; SEQ ID NO: 145
; LENGTH: 2458
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. US20030108871A1 1678695CB1
; US-09-919-039-145

Query Match          72.9%; Score 156.8; DB 10; Length 2458;
Best Local Similarity 88.5%; Pred. No. 1,5e-41;
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 11 GCTTAGAGAGTGTGCTGCGACAGTCCACTCTTTTCCGAGAGTGAATCCCGTTGCCAA 70
Db 1 GCTTAGAGAGTGTGCTGCGAGGCTCGCTTCTTTCGAGAGTGAATCCCGGCTCCAA 60

Qy 71 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGAGTTTCCGCGCTCCG 130
Db 61 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGCTGAGTTTCCGCGCTCCG 120

Qy 131 GAAGAGCCGAGCTTTCTGCGGAGTCCAGTGTTCGTTTCCAGCCCAATCTCAGAGCC 190
Db 121 GAAGAGCTAGCTTTGCTGCGGATCCGCTCCGCGTTTCCAGCCCAATCTCAGAGCG 180

Qy 191 GAGCCGACAGAG 202
Db 191 GAGCCGACAGAG 202
```

```

Db 181 GAGCCGACAGAG 192

RESULT 10
US-10-335-053-290
; Sequence 290, Application US/10335053
; Publication No. US20040241653A1
; GENERAL INFORMATION:
; APPLICANT: Quark Biotech, Inc.
; TITLE OF INVENTION: Methods for identifying marker genes for cancer
; FILE REFERENCE: 68733-A; 070/US1
; CURRENT APPLICATION NUMBER: US/10/335,053
; CURRENT FILING DATE: 2003-03-27
; PRIOR APPLICATION NUMBER: 60/345,317
; PRIOR FILING DATE: 2001-12-31
; NUMBER OF SEQ ID NOS: 319
; SOFTWARE: Patentin version 3.2
; SEQ ID NO: 290
; LENGTH: 2513
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-335-053-290

Query Match          72.9%; Score 156.8; DB 18; Length 2513;
Best Local Similarity 88.5%; Pred. No. 1,5e-41;
Matches 170; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 11 GCTTAGAGAGTGTGCTGCGACAGTCCACTCTTTTCCAGAGTGAATCCCGTTGCCAA 70
Db 1 GCTTAGAGAGTGTGCTGCGAGGCTCCGCTTCTTTCGAGAGTGAATCCCGGCTCCAA 60

Qy 71 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGTCCAGTTTCCGCGCTCCG 130
Db 61 GCGTTCCAGAGCGAACTGTGCGGCTGAGGACCGCGCGTCCAGTTTCCGCGCTCCG 120

Qy 131 GAAGAGCCGAGCTTTCTGCGGAGTCCAGTGTTCGTTTCCAGCCCAATCTCAGAGCC 190
Db 121 GAAGAGCTAGCTTTGCTGCGGATCCGCTCCGCGTTTCCAGCCCAATCTCAGAGCG 180

Qy 191 GAGCCGACAGAG 202
Db 181 GAGCCGACAGAG 192

RESULT 11
US-10-027-632-111980/C
; Sequence 111980, Application US/10027632
; Publication No. US2002019871A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: Polymorphisms in the Human Genome
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 111980
```

LENGTH: 2771
TYPE: DNA
ORGANISM: Human
US-10-027-632-111980

Query Match 72.7%; Score 156.4; DB 13; Length 2771;
Best Local Similarity 99.4%; Pred. No. 2.1e-41;
Matches 157; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 60
160 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 101
61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
100 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 41
121 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 158
40 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 3

RESULT 12
US-10-027-632-111980/c
Sequence 111980, Application US/10027632
Publication No. US20030204075A9

GENERAL INFORMATION:
APPLICANT: Wang, David G.
TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
FILE REFERENCE: 108827.129
CURRENT APPLICATION NUMBER: US/10/027,632
CURRENT FILING DATE: 2002-04-30
PRIOR APPLICATION NUMBER: US 60/218,006
PRIOR FILING DATE: 2000-07-12
PRIOR APPLICATION NUMBER: US 60/198,676
PRIOR FILING DATE: 2000-04-20
PRIOR APPLICATION NUMBER: US 60/193,483
PRIOR FILING DATE: 2000-03-29
PRIOR APPLICATION NUMBER: US 60/185,218
PRIOR FILING DATE: 2000-02-24
PRIOR APPLICATION NUMBER: US 60/167,363
PRIOR FILING DATE: 1999-11-23
PRIOR APPLICATION NUMBER: US 60/156,358
PRIOR FILING DATE: 1999-09-28
PRIOR APPLICATION NUMBER: US 60/146,002
PRIOR FILING DATE: 1999-08-09
NUMBER OF SEQ ID NOS: 325720
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 111980
LENGTH: 2771
TYPE: DNA
ORGANISM: Human
US-10-027-632-111980

Query Match 72.7%; Score 156.4; DB 17; Length 2771;
Best Local Similarity 99.4%; Pred. No. 2.1e-41;
Matches 157; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 60
160 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 101
61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
100 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 41
121 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 158
40 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCA 3

RESULT 13

US-10-363-345A-17429/c
Sequence 17429, Application US/10363345A
Publication No. US20040234960A1

GENERAL INFORMATION:
APPLICANT: Alexander Olek
APPLICANT: Christian Piepenbrock
TITLE OF INVENTION: Method for determining the degree of methylation of defined
FILE REFERENCE: E01/1227
CURRENT APPLICATION NUMBER: US/10/363,345A
CURRENT FILING DATE: 2003-03-03
NUMBER OF SEQ ID NOS: 40712
SEQ ID NO 17429
LENGTH: 595
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
OTHER INFORMATION: CPG-Island No: 17429
US-10-363-345A-17429

Query Match 67.5%; Score 145.2; DB 18; Length 595;
Best Local Similarity 79.9%; Pred. No. 8.9e-38;
Matches 171; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 60
454 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 395
61 GTTGTCCCAAGGCTTCCAGAGCGAAGCTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
394 GTTATCCCAAACTTCCCAAAAGCACTATACAGTCAAAACCGACGCTGAAATTT 335
121 CCGGCGTCCGAGAGACCGAGCTCTTTCGCGGATCCAAGTGTTCGTTTCCAGCCCA 180
334 CCGAGCTCCGAAAAAAGCAAGCTTTCGCGGATCCAATATTCGTTTCCAACTCCCA 275
181 TCTCAGAGCCGAGCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 214
274 TCTCAAAACCGAACCGAACCAAAACCG 241

RESULT 14
US-10-363-345A-17430
Sequence 17430, Application US/10363345A
Publication No. US20040234960A1

GENERAL INFORMATION:
APPLICANT: Alexander Olek
APPLICANT: Christian Piepenbrock
TITLE OF INVENTION: Method for determining the degree of methylation of defined
FILE REFERENCE: E01/1227
CURRENT APPLICATION NUMBER: US/10/363,345A
CURRENT FILING DATE: 2003-03-03
NUMBER OF SEQ ID NOS: 40712
SEQ ID NO 17430
LENGTH: 595
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
OTHER INFORMATION: CPG-Island No: 17430
US-10-363-345A-17430

Query Match 67.5%; Score 145.2; DB 18; Length 595;
Best Local Similarity 79.9%; Pred. No. 8.9e-38;
Matches 171; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

1 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 60
142 ATACGGCTAGCCTGAGAGGCTGCTGCGACAGTCACTTTTTCAGAGTGAATCC 201

```
OY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGCAGGACCGGCGCTCGAGTTT 120
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 202 GTTATCCCAAACTTCCCAAACTTAACGAACTATACGACTACAAACACCGACGCTCGAATT 261

OY 121 CCGGGGTCCGGAAGGACCGAGCTTTCTTCGCGGATCCAGTGTTCGTTTCAGCCCCAA 180
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 262 CCGAGTCCGAAACCGAACTCTTCTGCGAATCCAAATATTCGTTTCAGCCCCAA 321

OY 181 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 214
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 322 TCTCAAAACCGAACCGACCAAAACAAACCG 355
```

RESULT 15

```
US-10-363-20731/c
; Sequence 20731, Application US/10363345A
; Publication No. US20040234960A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Method for determining the degree of methylation of defined
; FILE REFERENCE: E01/1227
; CURRENT APPLICATION NUMBER: US/10/363,345A
; CURRENT FILING DATE: 2003-03-03
; NUMBER OF SEQ ID NOS: 40712
; SEQ ID NO 20731
; LENGTH: 596
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
; OTHER INFORMATION: CpG-island No: 20731
US-10-363-345A-20731
```

```
Query Match 67.5%; Score 145.2; DB 18; Length 596;
Best Local Similarity 79.9%; Pred. No. 8.9e-38;
Matches 171; Conservative 0; Mismatches 43; Indels 0; Gaps 0;
```

```
OY 1 ATAAAGGCTAGGCTGAGAGCTGCGACGAGTCCACTCTTTTCGAGAGTGACTCCC 60
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 545 ATAAAGCTAATCTTAATAAATACTAAGCAATCCACTACTTTTCGAAATTAATCCC 486

OY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGCAGGACCGGCGCTCGAATT 120
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 485 GTTATCCCAAACTTCCCAAACTTAACGAACTAATGACTACAAACCGAGCGCTCGAATT 426

OY 121 CCGGGGTCCGGAAGGACCGAGCTTTCTTCGCGGATCCAGTGTTCGTTTCAGCCCCAA 180
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 425 CCGAGTCCGAAACCGAACTCTTCTGCGAATCCAAATATTCGTTTCAGCCCCAA 366

OY 181 TCTCAGAGCCGACCGACAGAGAGGAGGACCG 214
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 365 TCTCAAAACCGAACCGACCAAAACAAACCG 332
```

Search completed: February 11, 2005, 09:47:21
Job time : 265 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using bw model

Run on: February 11, 2005, 07:40:18 ; Search time 1641 Seconds
(without alignments)
4987.092 Million cell updates/sec

Title: US-09-936-506-1

Perfect score: 215

Sequence: 1 ataacgcctagcctcgtgagag.....gacagagcagcggaaccgc 215

Scoring table: IDENTITY NUC

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 68479088

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:
1: gb_est1:
2: gb_est2:
3: gb_hic:
4: gb_est3:
5: gb_est4:
6: gb_est5:
7: gb_est6:
8: gb_gse1:
9: gb_gse2:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	214	99.5	642	7	CN397686 170005326
2	214	99.5	2380	3	CR605652 full-length
3	214	99.5	2383	3	CR598680 full-length
4	214	99.5	2387	3	CR626292 full-length
5	214	99.5	2391	3	CR608110 full-length
6	214	99.5	2396	3	CR599258 full-length
7	214	99.5	2398	3	CR618761 full-length
8	214	99.5	2398	3	CR621778 full-length
9	214	99.5	2398	3	CR606872 full-length
10	214	99.5	2401	3	CR595673 full-length
11	214	99.5	2409	3	CR624878 full-length
12	214	99.5	2417	3	CR603812 full-length
13	212.4	98.8	356	6	CB112917 K-EST0154
14	212.4	98.8	493	6	BO639435 h15e11.Y
15	212.4	98.8	511	6	CB154948 K-EST0213
16	212.4	98.8	527	6	CB141518 K-EST0195
17	212.4	98.8	590	6	CB138426 K-EST0191
18	212.4	98.8	701	4	BG773197 602721934
19	212.4	98.8	816	4	BG485554 602505445
20	212.4	98.8	982	4	B1462679 603202121
21	212	98.6	582	5	BP350439 BP350439
22	211.4	98.3	751	4	B1464037 603202811
23	211	98.1	570	5	BP259174 BP259174
24	210.8	98.0	582	5	BP245573 BP245573

25	210.8	98.0	584	5	BP232134 BP232134
26	210.4	97.9	267	1	AU076824 AU076824
27	210.4	97.9	316	4	BM622298 K-EST0093
28	210.4	97.9	376	6	CB133590 K-EST0184
29	210.4	97.9	409	6	CB133685 K-EST0184
30	210.4	97.9	436	4	B1548281 B1548281
31	210.4	97.9	463	6	CB137710 K-EST0189
32	210.4	97.9	479	6	CB133251 K-EST0184
33	210.4	97.9	505	6	CB133452 K-EST0185
34	210.4	97.9	509	6	CB134000 K-EST0185
35	210.4	97.9	509	6	CB138961 K-EST0191
36	210.4	97.9	516	6	CB137829 K-EST0190
37	210.4	97.9	516	6	CB138598 K-EST0191
38	210.4	97.9	522	6	CB133933 K-EST0185
39	210.4	97.9	523	6	CB152005 K-EST0209
40	210.4	97.9	523	6	CB152693 K-EST0209
41	210.4	97.9	526	6	BP382860 BP382860
42	210.4	97.9	532	6	CB153107 K-EST0210
43	210.4	97.9	533	6	CB133518 K-EST0184
44	210.4	97.9	546	6	CB155190 K-EST0213
45	210.4	97.9	581	5	BP231177 BP231177

ALIGNMENTS

RESULT 1
LOCUS CN397686 642 bp. mRNA linear EST 16-MAY-2004
DEFINITION 17000532601385 GRN_ES Homo sapiens cDNA 5', mRNA sequence.
ACCESSION CN397686
VERSION CN397686.1 GI:47385281
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 642)
Brandenberger, R., Wei, H., Zhang, S., Lei, S., Murage, J., Fisk, G.J.,
Li, Y., Xu, C., Fang, R., Guegler, K., Rao, M.S., Mandalam, R.,
Lebkowski, J. and Stanton, L.W.
Transcriptome characterization elucidates signaling networks that
control human ES cell growth and differentiation
Nat. Biotechnol. 22 (6), 707-716 (2004)
JOURNAL Contact: Brandenberger R
COMMENT Regenerative Medicine
Geron Corporation
230 Constitution Drive, Menlo Park, CA 94025, USA
Tel: 650 473 8658
Fax: 650 473 7760
Email: rbrandenberger@geron.com
Insert Length: 642 Std Error: 0.00.
Location/Qualifiers

FEATURES

1..642
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cissue_type="embryonic stem cells, cell lines H1, H7, and H9"
/clone_lib="GRN_ES"
/note="Oligo dT primed, full-length enriched cDNA library from undifferentiated hES cell lines H1 (p32), H7 (p29), and H9 (p26) maintained in feeder-free conditions"

ORIGIN

Query Match 99.5%; Score 214; DB 7; Length 642;
Best Local Similarity 100.0%; Pred. No. 6,6e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 ATTAAGGCTAGGCTAGAGAGCTGCTGGACAGTCCACATCACTTTTTCGAGATGACTCCC 60
DB 78 ATTAAGGCTAGGCTAGAGAGCTGCTGGACAGTCCACATCACTTTTTCGAGATGACTCCC 137

QY 61 GTTGTCCCAAGGCTTCCCAAGCGAACTGTGTGGGCTGAGGACCGGGCGCTCGAGTTT 120
Db 138 GTTGTCCCAAGGCTTCCCAAGCGAACTGTGTGGGCTGAGGACCGGGCGCTCGAGTTT 197
QY 121 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCTCACTGTTCCGTTTCCAGCCCCCA 180
Db 198 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCTCACTGTTCCGTTTCCAGCCCCCA 257
QY 181 TCTCAGAGCCGACCGACAGAGAGAGGAGACCG 214
Db 258 TCTCAGAGCCGACCGACAGAGAGAGGAGACCG 291

RESULT 2
CR605652
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

CR605652 2380 bp mRNA linear HTC 21-JUL-2004
Full-length cDNA clone CS0DF033YK03 of Fetal brain of Homo sapiens (human).
CR605652
HTC; CNSLT_cDNA.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 2380)
Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished
Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paraday Avenue
2 (bases 1 to 2380)
Genoscope.
Direct Submission
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : secrete@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
Location/Qualifiers
1..2380
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF033YK03"
/tissue_type="Fetal Brain"
/plasmid="pCMVSPORT_6"

FEATURES
source

Query Match 99.5%; Score 214; DB 3; Length 2380;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ORIGIN

RESULT 3
CR598680
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

CR598680 2383 bp mRNA linear HTC 21-JUL-2004
Full-length cDNA clone CS0DC028YK15 of Neuroblastoma Cot
25-normalized of Homo sapiens (human).
CR598680
HTC; CNSLT_cDNA.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 2383)
Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished
Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paraday Avenue
2 (bases 1 to 2383)
Genoscope.
Direct Submission
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : secrete@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
1st strand cDNA was primed with a NotI-oligo(dt) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
Location/Qualifiers
1..2383
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DC028YK15"
/tissue_type="Neuroblastoma Cot 25-normalized"
/plasmid="pCMVSPORT_6"

FEATURES
source

Query Match 99.5%; Score 214; DB 3; Length 2383;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ORIGIN

QY 1 ATAAAGGCTAGCTGAGAGCTGCTGCGACAGTCACACTCTTTTCGAGAGTGACTCCC 60
Db 14 ATAAAGGCTAGCTGAGAGCTGCTGCGACAGTCACACTCTTTTCGAGAGTGACTCCC 73
QY 61 GTTGTCCCAAGGCTTCCCAAGCGAACTGTGTGGGCTGAGGACCGGGCGCTCGAGTTT 120
Db 74 GTTGTCCCAAGGCTTCCCAAGCGAACTGTGTGGGCTGAGGACCGGGCGCTCGAGTTT 133
QY 121 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCTCACTGTTCCGTTTCCAGCCCCCA 180
Db 134 CCGGCGTCCGAAGACCGAGCTCTTCTCGCGATCTCACTGTTCCGTTTCCAGCCCCCA 193
QY 181 TCTCAGAGCCGACCGACAGAGAGAGGAGACCG 214
Db 194 TCTCAGAGCCGACCGACAGAGAGGAGACCG 227

RESULT 4
CR626292
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

CR626292 2387 bp mRNA linear HTC 21-JUL-2004
Full-length cDNA clone CS0DF038YK05 of Fetal brain of Homo sapiens (human).
CR626292
HTC; CNSLT_cDNA.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE	AUTHORS	TITLE	JOURNAL	REMARK
REFERENCE	Mammalia; Eutheria; Primates; Carnivora; Homiidae; Homo.			
AUTHORS	Li, W.B., Gruber, C., Jesssee, J. and Polayes, D.			
TITLE	Full-length cDNA libraries and normalization			
JOURNAL	Unpublished			
REMARK	Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Paradise Avenue			
REFERENCE	Genoscope.			
AUTHORS	2 (bases 1 to 2387)			
TITLE	Genoscope.			
JOURNAL	Submitted			
REMARK	Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : secrefgenoscope.cns.fr - Web : www.genoscope.cns.fr) 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five primers end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.			
FEATURES	Location/Qualifiers			
SOURCE	1..2387 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CS0DF038YK05" /tissue="type="Fetal brain" /plasmid="pCMVSPORT_6"			
ORIGIN				
Query Match	99.5% ; Score 214 ; DB 3 ; Length 2387 ;			
Best Local Similarity	100.0% ; Pred. 7.9e-51 ;			
Matches	214 ; Conservative 0 ; Mismatches 0 ; Indels 0 ; Gaps 0 ;			
QY	1 ATAAAGGCTAGCTCGAGAGAGCTGCTGCAGACAGTCCACTTCTTTTCAGAGTACTCC 60			
DB	14 ATAAAGGCTAGCTCGAGAGAGCTGCTGCAGACAGTCCACTTCTTTTCAGAGTACTCC 73			
QY	61 GTTGTCCTCAAGGCTTCCAGAGCCGAACCTGTGCGGCTCAGGACCGCGCGTCGATTT 120			
DB	74 GTTGTCCTCAAGGCTTCCAGAGCCGAACCTGTGCGGCTCAGGACCGCGCGTCGATTT 133			
QY	121 CCGGCGTCGCGAAGAGACCGGAGCTCTTTCGCGGAGCCAGATGTCCTTTCAGCCCCCA 180			
DB	134 CCGGCGTCGCGAAGAGACCGGAGCTCTTTCGCGGAGCCAGATGTCCTTTCAGCCCCCA 193			
QY	181 TCTCAGAGCCGAGCCGAGCAGAGAGAGAGGAAACG 214			
DB	194 TCTCAGAGCCGAGCCGAGCAGAGAGAGGAAACG 227			
RESULT 5				
LOCUS	CR608110 2391 bp mRNA linear HTC 21-JUL-2004			
DEFINITION	full-length cDNA clone CS0D004Y601 of T cells (Jurkat cell line)			
ACCESSION	CR608110			
VERSION	CR608110.1 GI:50488917			
KEYWORDS	HTC; cDNA.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;			
AUTHORS	Mammalia; Eutheria; Primates; Carnivora; Homiidae; Homo.			
TITLE	1 (bases 1 to 2391)			
JOURNAL	Li, W.B., Gruber, C., Jesssee, J. and Polayes, D.			
REMARK	Full-length cDNA libraries and normalization Unpublished Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Paradise Avenue 2 (bases 1 to 2391) Genoscope. Direct Submission Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : secrefgenoscope.cns.fr - Web : www.genoscope.cns.fr) 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five primers end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.			

BP 191 91006 EVRY cedex - FRANCE (E-mail: seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
let strand cDNA was primed with a NotI-oligo (dT) primer. Five primers
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.

FEATURES
SOURCE
location/Qualifiers
1..2391
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="GS01004YG01"
/tissue_type="T cells (Jurkat cell line) Cot
10-normalized."
/plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2391;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ATAAAGGCTAAGCTGAGAGAGCTGCTGAGACAGTCCACTACCTTTTTCAGAGTACTCCC 60
29 ATAAAGGCTAAGCTGAGAGAGCTGCTGAGACAGTCCACTACCTTTTTCAGAGTACTCCC 88
DB 61 GTGTGCTCCAAAGGCTTCCAGAGCAACCTGTGCGGCTGACAGCAACCGCGCTGAGATT 120
89 GTGTGCTCCAAAGGCTTCCAGAGCAACCTGTGCGGCTGACAGCAACCGCGCTGAGATT 148
OY 121 CCGGCGCTCCGAAAGACCGAGCTTTCTTCGGGATCCAGTGTTCGGTTTCCAGGCCCA 180
149 CCGGCGCTCCGAAAGACCGAGCTTTCTTCGGGATCCAGTGTTCGGTTTCCAGGCCCA 208
OY 181 TCTCAGAGCCGAGCGCAGACAGAGCAGAGAACCG 214
DB 209 TCTCAGAGCCGAGCGCAGACAGAGCAGAGAACCG 242

RESULT 6
CR599258
LOCUS
DEFINITION
full-length cDNA clone CS0DF007YE19 of Fetal Brain of Homo sapiens (human).
ACCESSION
CR599258
VERSION
CR599258.1
KEYWORDS
HTC; cNSLT cDNA.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1..2391
14.W.B., Gruber C., Jesse, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished
Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue
2 (bases 1 to 2396)
Genoscope.
Direct Submission
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
let strand cDNA was primed with a NotI-oligo (dT) primer. Five primers
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
location/Qualifiers
1..2396
/organism="Homo sapiens"
/mol_type="mRNA"

FEATURES
SOURCE

ORIGIN

/db_xref="taxon:9606"
/clone="CSODF007YF19"
/tissue="Fetal Brain"
/plasmid="pCMVSPORT_6"

Query Match

99.5%; Score 214; DB 3; Length 2396;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60
DB 14 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 73
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
DB 74 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTT 133
QY 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 180
DB 134 CCGGGCTCCGGAAGAACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 193
QY 181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 214
DB 194 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 227

RESULT 7
CR618761
LOCUS
DEFINITION CR618761 2398 bp mRNA linear HTC 21-JUL-2004
full-length cDNA clone CSODN003YF07 of Adult brain of Homo sapiens
(human).
ACCESSION CR618761 GI:50499568
VERSION CR618761.1
KEYWORDS HTC; cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
JOURNAL Full-length cDNA libraries and normalization
REMARK Unpublished

CONTACT : Feng Liang Email : fliang@life.techn.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue
Genoscope.
REFERENCE 2 (bases 1 to 2398)
AUTHORS
TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.

FEATURES
source
1..2398
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODN003YF07"
/tissue_type="Adult brain"
/plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2396;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60
|||||

DB 29 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 88

QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTT 120

DB 89 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTT 148

QY 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 180

DB 149 CCGGGCTCCGGAAGAACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 208
181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 214
209 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 242

RESULT 8
CR621778
LOCUS
DEFINITION CR621778 2398 bp mRNA linear HTC 21-JUL-2004
full-length cDNA clone CSODF003YF16 of Placenta of Homo sapiens
(human).
ACCESSION CR621778 GI:50502585
VERSION CR621778.1
KEYWORDS HTC; cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
JOURNAL Full-length cDNA libraries and normalization
REMARK Unpublished

CONTACT : Feng Liang Email : fliang@life.techn.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue
Genoscope.
REFERENCE 2 (bases 1 to 2398)
AUTHORS
TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.

FEATURES
source
1..2398
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODF003YF16"
/tissue_type="Placenta"
/plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2396;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60
DB 14 ATAAAGGCTAGCCTGAGAGAGCTGCTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 73
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTT 120
DB 74 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTGAGTTT 133
QY 121 CCGGGCTCCGGAAGAACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 180
DB 134 CCGGGCTCCGGAAGAACCGAGCTCTTCTCGCGGATCCAGTGTTCGTTCCAGCCCCCA 193
181 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 214
|||||

Db 194 TCTCAGAGCCGAGCCGACAGAGAGGAAACCG 227

RESULT 9
CR606872
LOCUS
DEFINITION CR606872 2399 bp mRNA linear HTC 21-JUL-2004
full-length cDNA clone CS0DF021Y109 of Fetal Brain of Homo sapiens (human).

ACCESSION
VERSION CR606872.1 GI:50487679
KEYWORDS
SOURCE HTC; CNSLT; cDNA.
ORGANISM Homo sapiens (human)

REFERENCE
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/InvitrogenCorporation1600
Faraday Avenue
2 (bases 1 to 2399)

REFERENCE
AUTHORS Genoscope.
TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail: sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES
SOURCE
Location/Qualifiers
1..2399
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF021Y109"
/tissue_type="Fetal brain"
/plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2399;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTCGAGAGTGACTCCC 60
DB 14 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTCGAGAGTGACTCCC 73

QY 61 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTCGAGTTT 120
DB 74 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTCGAGTTT 133

QY 121 CCGGGTCCGAGAGACCGAGCTCTTCTCGCGAGATCCAGTGTTCGTTTCCAGCCCA 180
DB 134 CCGGGTCCGAGAGACCGAGCTCTTCTCGCGAGATCCAGTGTTCGTTTCCAGCCCA 193

QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 214
DB 194 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 227

RESULT 10
CR595673
LOCUS
DEFINITION CR595673 2401 bp mRNA linear HTC 21-JUL-2004
full-length cDNA clone CS0DE002YK13 of Placenta of Homo sapiens (human).

ACCESSION
VERSION CR595673.1 GI:50476480
KEYWORDS
SOURCE HTC; CNSLT; cDNA.
ORGANISM Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/InvitrogenCorporation1600
Faraday Avenue
2 (bases 1 to 2401)

REFERENCE
AUTHORS Genoscope.
TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail: sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized. Library was constructed by Life Technologies, a division of Invitrogen.

FEATURES
SOURCE
Location/Qualifiers
1..2401
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DE002YK13"
/tissue_type="Placenta"
/plasmid="pCMVSPORT_6"

ORIGIN

Query Match 99.5%; Score 214; DB 3; Length 2401;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTCGAGAGTGACTCCC 60
DB 29 ATACGGCTAGCCTGAGAGCTGTGCGACAGTCCACTTCTTTCGAGAGTGACTCCC 88

QY 61 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTCGAGTTT 120
DB 89 GTTGTCCTCAGAGCTTCCAGAGCGAACTGTGCGGCTGAGGACCGGCGCTCGAGTTT 148

QY 121 CCGGGTCCGAGAGACCGAGCTCTTCTCGCGAGATCCAGTGTTCGTTTCCAGCCCA 180
DB 149 CCGGGTCCGAGAGACCGAGCTCTTCTCGCGAGATCCAGTGTTCGTTTCCAGCCCA 208

QY 181 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 214
DB 209 TCTCAGAGCCGAGCCGACAGAGAGAGGAAACCG 242

RESULT 11
CR624878
LOCUS
DEFINITION CR624878 2409 bp mRNA linear HTC 21-JUL-2004
full-length cDNA clone CS0DF012YK23 of Fetal Brain of Homo sapiens (human).

ACCESSION
VERSION CR624878.1 GI:50505685
KEYWORDS
SOURCE HTC; CNSLT; cDNA.
ORGANISM Homo sapiens (human)

REFERENCE
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/InvitrogenCorporation1600
Faraday Avenue
2 (bases 1 to 2409)

REFERENCE
AUTHORS Genoscope.

TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES
source
1..2409
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF012YA23"
/tissue_type="Fetal brain"
/plasmid="pCMVSPORT_6"

ORIGIN
Query Match 99.5%; Score 214; DB 3; Length 2409;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATTAAGGCTACGCTGAGAGCTGCTGCGACATCCACTCTTTTCCAGAGTACTCCC 60
DB 14 ATTAAGGCTACGCTGAGAGCTGCTGCGACATCCACTCTTTTCCAGAGTACTCCC 73
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACACCGCGCTGAGTTT 120
DB 74 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACACCGCGCTGAGTTT 133
QY 121 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180
DB 134 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 193
QY 181 TCTCAGAGCCGAGCCGACAGAGAGCGAGAACCG 214
DB 194 TCTCAGAGCCGAGCCGACAGAGAGCGAGAACCG 227

RESULT 12
LOCUS CR603812 2417 bp mRNA linear HMC 21-JUL-2004
DEFINITION Full-length cDNA clone CS0DF020YJ02 of Fetal brain of Homo sapiens
(human).
ACCESSION CR603812
VERSION CR603812.1 GI:50484619
KEYWORDS HTC; CDS; cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 2417)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
JOURNAL Full-length cDNA libraries and normalization
TITLE Unpublished
CONTACT : Feng Liang Email : fliang@life.techn.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
REMARK Faraday Avenue
2 (bases 1 to 2417)
REFERENCE
AUTHORS Genoscope.
JOURNAL Direct Submission
TITLE Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES
source
1..2417
/organism="Homo sapiens"

ORIGIN
Query Match 99.5%; Score 214; DB 3; Length 2417;
Best Local Similarity 100.0%; Pred. No. 7.9e-51;
Matches 214; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATTAAGGCTACGCTGAGAGCTGCTGCGACATCCACTCTTTTCCAGAGTACTCCC 60
DB 29 ATTAAGGCTACGCTGAGAGCTGCTGCGACATCCACTCTTTTCCAGAGTACTCCC 88
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACACCGCGCTGAGTTT 120
DB 89 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGAGGACACCGCGCTGAGTTT 148
QY 121 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 180
DB 149 CCGGCGTCCGGAAGAGACCGAGCTCTTCTGCGGATCCAGTGTTCGTTCCAGCCCCCA 208
QY 181 TCTCAGAGCCGAGCCGACAGAGAGCGAGAACCG 214
DB 209 TCTCAGAGCCGAGCCGACAGAGAGCGAGAACCG 242

RESULT 13
LOCUS CB112917 356 bp mRNA linear EST 28-JAN-2003
DEFINITION K-EST0154803 L6Chock0 Homo sapiens cDNA clone L6Chock0-10-A11 5',
mRNA sequence.
ACCESSION CB112917
VERSION CB112917.1 GI:27938724
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 356)
AUTHORS Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R.,
Oh, K.U., Cheong, J.E., Sohn, H.Y., Kim, J.W., Park, H.S., Kim, S. and
Kim, Y.S.
JOURNAL 21C Frontier Korean EST Project 2001
COMMENT Unpublished (2002)
CONTACT: Kim YS
Genome Research Center
Korea Research Institute of Bioscience & Biotechnology
52 Boeun-dong Yuseong-gu, Daejeon 305-353, South Korea
Tel: +82-42-860-4470
Fax: +82-42-860-4409
Email: yongsung@mail.kribb.re.kr
Plate: 10 row: A column: 11
High quality sequence stop: 356.
FEATURES
source
1..356
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="L6Chock0-10-A11"
/sex="M"
/cell_line="Cho-CR"
/lab_host="Top10F"
/clone_id="L6Chock0"
/note="Organ: Liver; Vector: pcns-D2, Site_1: EcoRI;
Site_2: NotI; The poly (A)+ RNA was dephosphorylated with
bacterial alkaline phosphatase (BAP) and then deacapped
with tobacco acid pyrophosphatase (TAP). The deacapped
intact mRNA was ligated with DNA-RNA linker including
EcoRI site by treatment of T4 RNA ligase and the first
strand cDNA was synthesized from oligo dt-selected mRNA by
priming with dt-tailed vector. The dt-tailed vector was

adjusted to have about 60nt. The cDNA vector was circularized with E. coli DNA ligase after digestion of EcoRI which site is also included in vector. An RNA strand converted to a DNA strand by Okayama-Berg method. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

ORIGIN

Query Match 98.8%; Score 212.4; DB 6; Length 356;
Best Local Similarity 99.5%; Pred. No. 1.7e-50;
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGAGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 60
DB 1 ATAAAGGCTAGAGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 60
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 120
DB 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 120
QY 121 CCGGGCTCCGAGAGACCGAGCTCTTTCGCGGATCCAGTTCGTTTCCAGCCCCCA 180
DB 121 CCGGGCTCCGAGAGACCGAGCTCTTTCGCGGATCCAGTTCGTTTCCAGCCCCCA 180
QY 181 TCTCAGAGCCGACCGACAGAGAGGAAACCG 214
DB 181 TCTCAGAGCCGACCGACAGAGAGGAAACCG 214

RESULT 14
B0639435 493 bp mRNA linear EST 15-JUL-2002
LOCUS he15e11.y1 Human Retina cDNA (Un-normalized, unamplified): hd/he
DEFINITION Homo sapiens cDNA clone he15e11 5', mRNA sequence.
ACCESSION B0639435
VERSION B0639435.1 GI:21763894
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 493)
Wistow, G., Bernstein, S.L., Wyatt, M.K., Ray, S., Behal, A.,
Touchman, J.W., Bouffard, G., Smith, D. and Peterson, K.,
Expressed sequence tag analysis of human retina for the NEIBank
Project: Retbindn, an abundant, novel retinal cDNA and alternative
splicing of other retina-preferred gene transcripts
Mol. Vis. 8 (4), 196-204 (2002)
22103461
12107411

COMMENT Contact: Wistow G
Section on Molecular Structure and Function
National Eye Institute
6/331, NIH, Bethesda, MD 20892-2740, USA
Tel: 301 402 3452
Fax: 301 496 0078
Email: gwaem@helix.nih.gov
Plate: 15 row: e column: 11
Seq primer: M3RPI reverse primer (AB1).
Location/Qualifiers
1..493
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="he15e11"
/tissue="Retina"
/dev_stage="Adult"
/lab_host="EMD108"
/clone_lib="Human Retina cDNA (Un-normalized,
unamplified): hd/he"
/note="Organ: Eye; Vector: pSPORT1; Neural retina tissue

FEATURES
source

ORIGIN

Query Match 98.8%; Score 212.4; DB 5; Length 493;
Best Local Similarity 99.5%; Pred. No. 1.8e-50;
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATAAAGGCTAGAGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 60
DB 10 ATAAAGGCTAGAGCTGCTGCGACAGTCCACTCTTTTCAGAGTGAATCCC 69
QY 61 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 120
DB 70 GTTGTCCCAAGGCTTCCAGAGCGAACTGTGCGGCTGACGACCGGCGCTGAGTTT 129
QY 121 CCGGGCTCCGAGAGACCGAGCTCTTTCGCGGATCCAGTTCGTTTCCAGCCCCCA 180
DB 130 CCGGGCTCCGAGAGACCGAGCTCTTTCGCGGATCCAGTTCGTTTCCAGCCCCCA 189
QY 181 TCTCAGAGCCGACCGACAGAGAGGAAACCG 214
DB 190 TCTCAGAGCCGACCGACAGAGAGGAAACCG 223

RESULT 15
CB154948 511 bp mRNA linear EST 29-JAN-2003
LOCUS K-EST0213039 B2N807043 Homo sapiens cDNA clone B2N807043-30-C11 5',
DEFINITION mRNA sequence.
ACCESSION CB154948
VERSION CB154948.1 GI:28140051
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 511)
Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R.,
Oh, K.J., Cheong, J.E., Sohn, H.Y., Kim, J.M., Park, H.S., Kim, S. and
Kim, Y.S.
21C Frontier Korean EST Project 2001
Unpublished (2002)
Contact: Kim YS
Genome Research Center
Korea Research Institute of Bioscience & Biotechnology
52 Boeun-dong Yuseong-gu, Daejeon 305-333, South Korea
Tel: +82-42-860-4470
Fax: +82-42-860-4409
Email: yongsung@mail.kribb.re.kr
Plate: 30 row: G column: 11
High quality sequence stop: 511.
Location/Qualifiers
1..511
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="B2N807043-30-C11"
/sex="M"
/lab_host="Top10F"
/clone_lib="B2N807043"
/note="Organ: Brain; Vector: pCNS-D2; Site 1: EcoRI;

was dissected from two 80 year old donors with no observed eye disease. 100ug of total RNA was used for library construction. A directionally cloned cDNA library in the pSPORT1 vector (Life Technologies) was constructed at Bioserve Biotechnology (Laurel MD) essentially following the protocols of the SuperScript Plasmid System full details of which are contained in the manufacturer's instruction manual (<http://www.lifetech.com/>). First strand synthesis was carried out using a Not I primer-adaptor (5'-pGATTAATTCTAGATCCGAGCGGCCGCC(T)15-3'). EST analysis was performed on the unamplified library at the NIH Intramural Sequencing Center (NISC)."

FEATURES
source

Site_2: NotI; The poly (A) + RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tobacco acid pyrophosphatase (TAP). The decapped intact mRNA was ligated with DNA-RNA linker including EcoRI site by treatment of T4 RNA ligase and the first strand cDNA was synthesized from oligo dt-selected mRNA by priming with dt-tailed vector. The dt-tailed vector was adjusted to have about 60nt. The cDNA vector was circularized with E. coli DNA ligase after digestion of EcoRI which site is also included in vector. An RNA strand converted to a DNA strand by Okayama-Berg method. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F' by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

ORIGIN

```

Query Match      98.8%; Score 212.4; DB 6; Length 511;
Best Local Similarity 99.5%; Pred. No. 1.8e-50;
Matches 213; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1  ATAAAGGCTAGGCTGAGAGAGTGTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60
      |||
DB      1  ATAAAGGCTAGGCTGAGAGAGTGTGCGACAGTCCACTCTTTTCGAGAGTGAATCCC 60

QY      61  GTTGTCCCAAGGCTTCCAGACGAACTGTGCGGCTGCGAGCACCGGCGCTCGAGTTT 120
      |||
DB      61  GTTGTCCCAAGGCTTCCAGACGAACTGTGCGGCTGCGAGCACCGGCGCTCGAGTTT 120

QY      121  CCGGGCTCCGGAAGACCGAGTCTTCTGCGGATTCAGTTCGTTCCAGCCCCCA 180
      |||
DB      121  CCGGGCTCCGGAAGACCGAGTCTTCTGCGGATTCAGTTCGTTCCAGCCCCCA 180

QY      181  TCTCAGAGCCGACCGACAGAGAGGGAACCG 214
      |||
DB      181  TCTCAGAGCCGACCGACAGAGAGGGAACCG 214
  
```

Search completed: February 11, 2005, 09:02:43
 Job time : 1646 secs